YEAR IN REVIEW

Institute for Molecular Bioscience 2016 Annual Report CONTENTS

ABOUT 4 2016 snapshot 6 Message from the Vice-Chancellor and President 8 Message from the Director 10 2016 highlights 12

DISCOVERY 14 Feature: Shining a diagnostic light on rare diseases 16 Feature: Scientists developing new diagnostic techniques in the fight against superbugs 18 Feature: At the centre of it all, could understanding inflammation provide the silver bullet? 19 Feature: The mysterious language of pain and the fight to switch it off 20 Feature: Growing new organs – science fiction or science future? 22 Grants and fellowships 24 2016 award highlights 26

LEARNING 28 Research training 30 Research Higher Degree students 32 2016 RHD conferrals 34

ENGAGEMENT 36 Research commercialisation 38 Community engagement 40 Global collaborations 42

OUR PEOPLE 44 IMB boards and committees 46 Our people 47 Joint appointments and affiliates 50 Science ambassadors 51

SUPPORTING INFORMATION 52 Financial statement 54 Research grants 55 Research facilities 61 Publications 64

GIVING 66 Discoveries inspired by life 66

THANK YOU TO OUR SUPPORTERS 67

2 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 3 ABOUT

The University of Queensland’s Our research is framed through MISSION RESEARCH CENTRES STRATEGIC PRIORITIES Institute for Molecular six research centres focusing on superbug infection, pain, heart disease, Our mission is to advance scientific Centre for Inflammation Discovery excellence Bioscience (IMB) is a global inflammation, solar biotechnology and the knowledge and deliver new health and and Disease Research Translational impacts leader in multidisciplinary life industry applications from the best in interplay of genomics and disease. We Centre for Pain Research Learning sciences research. IMB brings also undertake research in cancer, the life sciences research. Centre for Superbug Solutions Leadership and engagement environment and agricultural solutions. together 500 researchers, Centre for Solar Biotechnology VISION Equity and sustainability students and support staff IMB’s combination of genomics, UQ Project Three Billion biostatistical, biological, from across the globe, using Our vision is to be a global leader in the UQ Centre for Cardiac and pharmacological and chemical life sciences research for discovery and application of molecular Vascular Biology disease discovery, application researchers means the Institute can life sciences research. take life science discoveries from the and sustainable futures. genome to drug design and application – for health, disease and for the sustainable solutions for our cities, fuels and foods. With 66 patents and 11 spin- outs to our name, UQ’s IMB is driven to SHARE IN OUR DISCOVERIES using life science research for discovery, Subscribe to our IMB news and event updates invention and application. imb.uq.edu.au/subscribe

JOIN OUR SOCIAL COMMUNITIES

Twitter.com/IMBatUQ Facebook.com/InstituteforMolecularBioscience Youtube.com/IMBatUQ

THE IMPACT OF OUR RESEARCH SPANS THE AREAS OF

Agriculture Cancer Solar Diabetes Infection Pain biotechnology and obesity

Heart and Inflammation Brain injury Rare and Superbugs cardiovascular and disease complex diseases diseases

4 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 5 2016 SNAPSHOT

research centres 5 total research income 4 38 patent families managed

Centre for Pain Research $30.1M competitive funding 7 4 agricultural/industrial biotechnology 20.1 30.1 21 Centre for Inflammation and Disease Research $20.1M operating 7 diagnostic/devices Centre for Superbug Solutions $5M philanthropy, commercialisation, 6 6 drug discovery tools UQ Centre for Cardiac and Vascular Biology other income and recoveries 21 therapeutics Centre for Solar Biotechnology UQ Project Three Billion $ world-class research facilities 10M 9 8 active Australian Research Council Linkage Projects $ with industry partners awarded from the 2.3M National Health and Medical Research Council grant awarded 500 from the 60 new partnerships researchers, postgrad students & support staff formed in 2016 Honours, undergraduate, $ occupational trainee and 4.5M coursework masters students hosted at IMB > % awarded 5 to establish the new ACRF 7 from the Cancer Ultrastructure and of IMB's publications include 121 % Australian Research Council Function Facility new patents filed industry collaborations active research higher degree students 100 honours students 364 achieved first class honours publications 4 Thomson Reuters Highly inflammatory disease Cited Researchers 41 research research higher degree secured up to a students graduated $22M over 1000 collaborations in global investment 40 Host of one of the largest biotech 7 Series A investments for high-impact scientific Fellows of the Australian the Queensland Emory intellectual property originating 57 publications Academy of Science Drug Discovery Initiative (QEDDI) from an Australian university countries

6 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 7 In 2016 the University advanced by In 2016, their innovation delivered By partnering with them in 2016, 22 places in the Academic Ranking of outcomes of global significance: IMB has: MESSAGE FROM THE World Universities, to rank 55th globally They started work on a new Created an organic insecticide that is and second in Australia. UQ is the only generation of drugs to be grown in protecting cotton crops and saving Australian university to rank in the top VICE-CHANCELLOR AND plants; bees; 20 for life sciences – an impressive achievement. As our largest institute, They identified a treatment target for Uncovered compounds in tarantula the Institute for Molecular Bioscience aggressive forms of breast cancer; venom that are a potential treatment plays a significant role in UQ’s success. They grew beating human heart for sheep parasites, a major cost for tissue from stem cells that will one the international sheep industry; However, research excellence in itself day be used to regenerate the hearts Made clean fuel from green algae; PRESIDENT is insufficient for translating discoveries of patients with heart disease; into meaningful outcomes with Attracted $22 million in global They made a discovery that investment to develop new treatments A clear measure of success in science is the impact that discoveries have on the world and the substantial impact. Such translation also could lead to a new treatment for inflammatory diseases such as lives of its people. The University of Queensland (UQ) has earned an international reputation for requires engagement with exceptional partners in industry, government and for Parkinson’s disease, and has Parkinson’s and asthma; excellence in research, as signified by our performance in international rankings. the community, and with researchers potential applications for nearly 50 Developed environmentally friendly who are connected across disciplines. other disorders; cane toad traps to catch tadpoles They progressed the development of before they can reproduce; and This is why the Institute for Molecular new drugs that target the underlying Developed a model to more Bioscience is multidisciplinary. It brings cause of diabetes; accurately forecast CO2 emissions. together researchers with different They identified four new classes of perspectives and expertise, who share The discoveries made at the Institute compounds that act against drug- one goal: high quality Discovery and and their applications attest to the resistant tuberculosis; Translation. They exchange ideas power of a multi-disciplinary approach across fields and challenge each other They identified interactions between to creating impact in Life Sciences to look at things differently, to ask new immune system pathways that could research. questions, and to create new areas of improve treatment of autoimmune I congratulate Director Professor science. They are working with partners and inflammatory diseases; Brandon Wainwright and the Institute on local problems with global impact, They discovered a protein in spider for Molecular Bioscience team. Their forging research discoveries with broad venom that binds to and inhibits pain curiosity in 2016 made an impressive application to combatting disease and receptors, uncovering a promising contribution to advancing human other global challenges. future treatment for chronic pain; and knowledge, to creating change and to They found a diagnosis for some of solving some of the world’s greatest the many Australians suffering from challenges. unresolved rare diseases. Professor Peter Høj Industry, international collaborators and Vice-Chancellor and President funding bodies alike are recognising the The University of Queensland Institute’s ability to translate discoveries into solutions.

8 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 9 MESSAGE FROM THE DIRECTOR

Improving quality of life is Here are some examples: IMB secured funding, through an IMB INNOVATORS MAKING DISCOVERY DRIVES US FORWARD Australian Research Council Linkage AN IMPACT the goal of research at IMB, We created the world’s first molecule Solutions to some of life’s most Infrastructure, Equipment and from discovering new ways to bank, crowdsourcing antibiotic One of the greatest signatures of the complicated problems lie in discovering Facilities grant and an Australian compounds from across the globe, enduring quality of our achievements is the essence of life itself. Disease diagnose and treat disease to Cancer Research Foundation to find new antibiotics to fight drug- our staff and research training students. discovery epitomises the mission of the providing sustainable solutions grant, to acquire new light imaging resistant superbugs. Their success mirrors our investment in IMB to translate our research to improve to fuel and food production. technologies that will set the Institute their development and our belief in their the sustainability of life, from agriculture, We have developed an app that uses and The University of Queensland The IMB provides solutions courage and capabilities. The quality to clean cities, to disease solutions. Our DNA sequence data to rapidly detect at the forefront of scientific imaging to some of the world’s most of their work can be epitomised in the many collaborators, industry partners, antibiotic resistant genes in bacteria capability. The acquisition of the following notes of acclaim. and our generous donors support pressing problems. to help limit the spread of superbugs. Lattice Light Sheet Microscope, for that goal and believe in our mission. I To enhance our ability to bring example - one of only a handful in Postdoctoral Research Fellow Dr We developed a chronic pain App acknowledge and thank them for their discovery to disease application and the world - will allow researchers to Rebecca Coll received the 2016 that will allow medical professionals support. sustainable futures, we launched a watch and record cancer cells in real Research Australia Discovery Award for to monitor and improve treatments translation sub-committee in 2016. Its time, and recreate the cells in three her work on identifying promising anti- I also acknowledge the professional based on patient data. mission is to ensure partnership and dimensions. inflammatory compounds that block the support staff that underpin We repurposed glucose monitoring NLRP3 inflammasome, a key driver of our progress; each of us has a engagement is fostered throughout the We launched the Queensland Facility technology to develop a low cost, inflammation. contribution to make and an impact Institute, from research training students for Advanced Genome Editing to postdoctoral fellows and senior portable test for a range of infectious to leave. Together, we have had (QFAGE) to provide rapid, precise and The Commonwealth Health Minister’s faculty. Indeed, this culture of translation diseases like Zika Virus, using a some outstanding achievements and low-cost genome editing technology Award for Excellence in Health and and innovation is what sets IMB apart. microchip plugged into a smartphone. successes in 2016 and I am proud to that is revolutionising functional Medical Research was awarded to lead an exceptional team who make genomic research. Group Leader and Research Fellow Dr Chairing the sub-committee is Bob We commenced UQ Project Three a valuable contribution to improving Billion (UQ3B) to identify and Joseph Powell. As the only Queensland Christiansen, who is a Knowledge We established the Centre for Solar the lives and health of all Australians determine the functional significance recipient in the Award’s 16-year history, Nation 100 founder and who is helping Biotechnology to optimise algae through leading discovery research. of variation in the genome and the prestigious award recognised Australia to capitalise on the changing production for the development of technological landscape to ensure the to decode the critical DNA base Joseph’s research into the ways genetic innovative biotechnologies to enhance Professor Brandon Wainwright nation’s prosperity. changes that influence disease differences in humans can affect future sustainability. Director, Institute for Molecular processes. disease susceptibility. Like the Knowledge Nation 100, Bioscience IMB is capitalising on technological We opened the new Ramaciotti Professor Kirill Alexandrov received advancements to increase our rate of Facility for Producing a Bill and Melinda Gates Foundation discovery, drive translation, and find Pharmaceuticals in Plants, potentially Grand Challenges Explorations grant new solutions to old problems. transforming sunflower seeds, tea to develop a low-cost diagnostic tool leaves and even potato chips into the that uses well-established glucose drug delivery packages of the future. biosensors to detect DNA of infectious pathogens.

One of UQ’s most highly-funded National Health and Medical Research Council (NHMRC) projects was awarded to Associate Professor Ben Hogan. He received a $1,228,364 project grant to investigate the molecular mechanisms behind cerebral cavernous malformations, common vascular anomalies that can lead to stroke.

10 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 11 2016 HIGHLIGHTS PARTNERING WITH INDUSTRY FOR BETTER HEALTH

Inflazome Ltd, a company founded on research from the IMB Centre for Inflammation and Disease Research and Trinity College Dublin, closed a Series A financing round of RECOGNISING GLOBAL IMPACT up to €15 million (A$22 million) to develop better treatments for inflammatory disorders including Parkinson’s disease IMB researchers Professors Grant Montgomery, Peter and asthma. The investment, co-led by two top global life Visscher, Phil Hugenholtz and Dr Mark Butler were science investment firms, Novartis Venture Fund and Fountain named as some of the world’s most influential scientific Healthcare Partners, is one of the largest biotech Series minds, as measured by the Thomson Reuters Highly A investments for intellectual property originating from an Cited Researchers list. The annual list recognises leading Australian university. researchers who rank in the top one per cent by citations for their field.

RIGHT PROFESSOR PETER VISSCHER LEFT INFLAMMATION RESEARCHERS ASSOCIATE PROFESSOR KATE SCHRODER (LEFT) AND DR REBECCA COLL (RIGHT)

BRINGING GROUND-BREAKING DISCOVERIES TO MARKET

IMB spin-out company Protagonist Therapeutics Inc. listed on the NASDAQ and was named Australian Company of the Year at the AusBiotech and Johnson & Johnson’s Innovation Industry Excellence Award. The clinical-stage biopharmaceutical company, founded by IMB researcher Associate Professor Mark Smythe, is developing oral drugs to treat gastrointestinal disorders such as inflammatory bowel disease.

TRACKING AND VISUALISING CANCER

IMB researchers will soon be able to see cancer cells grow, spread and respond to drugs in real time, using three new hi-tech microscopes. A $2.3 million grant from the Australian Cancer Research Foundation (ACRF) and $840 000 from the Australian Research Council Linkage Infrastructure, Equipment ABOVE QUEENSLAND PREMIER ANNASTACIA PALASZCZUK (LEFT) WITH PROFESSOR DAVID CRAIK (RIGHT) and Facilities scheme was awarded to the Institute for Molecular Bioscience to establish the new ACRF ABOVE IMB EARLY CAREER RESEARCHERS AT BRISBANE’S 2016 HEALTHHACK Cancer Ultrastructure and Function Facility. GROWING MEDICINE IN PLANTS The new Facility will provide pioneering imaging CREATING CHANGE THROUGH Queensland Premier Annastacia Palaszczuk opened the capabilities for tracking and visualising cancer, ENTREPRENEURSHIP world-class Clive and Vera Ramaciotti Facility for Producing which will help researchers learn how cancer cells Pharmaceuticals in Plants at IMB. The Facility was made behave and change, and develop new treatments to Inspired to innovate, our early career researchers won possible through a generous $1 million Ramaciotti Biomedical control cancer. The combination of advanced optical first and third prize at Brisbane’s 2016 HealthHack, Research Award from the Clive and Vera Ramaciotti and electron microscopy technology, and a skilled which brings together researchers, software developers, Foundation and trustee Perpetual. Led by Professor David multidisciplinary research team, means scientists can designers, healthcare professionals and students to find Craik and La Trobe University collaborator Professor Marilyn break through roadblocks that have stood in their solutions to health and medical problems. The winning Anderson AO, the new Facility will transform plants into path towards developing effective treatments. team developed an app to track and map the presence of antibiotic-resistant bacteria, which could rapidly alert ‘biofactories’ to produce next-generation medicines that can ABOVE PROFESSOR ALPHA YAP (RIGHT) SPEAKING be grown in fields rather than factories. AT THE ACRF CHAIRMAN’S DINNER clinicians so they can limit the spread of bacteria and fight an outbreak in real-time.

12 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 13 DISCOVERY

14 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 15 SHINING A DIAGNOSTIC LIGHT ON RARE DISEASES

Navigating the challenges of Rare diseases researcher Associate CHANGE ON THE HORIZON FOR GENOME STUDY OFFERS NEW “Through the use of next-generation UQ PROJECT THREE BILLION Professor Carol Wicking from the RARE DISEASES HOPE FOR CHILDREN WITH RARE sequencing-based WES we were able a rare disease is often marked At the end of 2016 IMB’s Centre for Institute for Molecular Bioscience (IMB), DISEASES to dramatically increase the diagnostic with feelings of confusion, Technological advances are driving Rare Disease Research joined with said approximately one in 12 Australians yield and reduce the time to diagnosis.” change for rare diseases, with scientists Contributing to the increasing number other research groups at UQ as part of fear of the unknown, and are living with a rare disease, many of now able to sequence every gene, or of genetic diagnoses is IMB’s Dr Cas The diagnoses led to refinements UQ Project Three Billion (UQ3B). desperation for more whom are children. in some cases every one of the three Simons. He is part of an international in some patients’ clinical care, with This multidisciplinary team of information and support. “Although individually rare, these billion base pairs that make up an team who used advanced genome families carrying certain mutations researchers will apply advanced diseases are collectively common. individual’s DNA. sequencing to diagnose 30 patients referred to specialised clinics for techniques in DNA and RNA Diagnosis – if it happens at all – is often with unresolved rare diseases. monitoring for cancer. “In many cases a rare disease may be sequencing, statistical genomics, delayed and difficult, with many people primarily caused by a single mistake The patients were among 70 people “Standard approaches to diagnose epigenetics and functional biology, to misdiagnosed at least once,” she said. in one of these base pairs. With new with leukodystrophies, a group of white matter disorders, such as MRI, decode the critical base changes that “Rare diseases can be life threatening and technology we can potentially find these genetic disorders that affect the brain’s fail nearly 50 per cent of these children, affect disease processes and explain chronically debilitating, and often there mistakes in a fraction of the time and white matter, and were examined using complicating their care and exacting a variation between individuals. are no effective treatments available. cost compared to just five or six years whole exome sequencing (WES) — a substantial psychological toll on families.” The ultimate goal is to develop new ago,” Associate Professor Wicking said. method that looks at all the genes in a “Families with rare diseases can The researchers concluded that adding diagnostic methods and treatments person’s genetic code at once. feel forgotten as they try to access “As a result, the past decade has seen whole-exome sequencing to the across a range of rare and complex diagnoses or treatment, while clinicians an explosion in the number of rare White matter disorders, which affect one diagnostic tools at clinicians’ disposal diseases. are frustrated as they strive to achieve diseases for which the underlying in 7000 children born each year, damage could decrease the number of patients the best outcomes for patients, defective gene(s) is known. the nerves that connect different brain with unsolved genetic white matter UQ PROJECT THREE BILLION (UQ3B) some with diseases they have never regions to each other and the spinal disorders from 50 per cent to less than “Genetic diagnosis is important encountered before.” cord, causing impaired brain function. 30 per cent. DIRECTOR Professor Grant Montgomery because knowing the underlying DEPUTY DIRECTORS Professor Naomi Wray, Associate Professor Carol Wicking cause of a disease may inform future Dr Simons said white matter disorders WEBSITE imb.uq.edu.au/project-three-billion reproductive choices for families, and could have a devastating impact on EMAIL [email protected] can provide hope in moving toward patients and families. improved treatment and tailored disease “Our study found that next-generation management. It can also offer families sequencing could shed light on an the opportunity to connect with other especially challenging group of genetic families who are trying to navigate disorders that impact the brain’s white through life living with the same disease.” matter,” he said.

16 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 17 SCIENTISTS DEVELOPING NEW DIAGNOSTIC TECHNIQUES AT THE CENTRE OF IT ALL, COULD UNDERSTANDING INFLAMMATION IN THE FIGHT AGAINST SUPERBUGS PROVIDE THE SILVER BULLET?

The rapid emergence of BACTERIAL OR VIRAL? DEVELOPING FASTER SUPERBUG TESTS resistant bacteria has posed One of the teams new inventions, born “This could lead to new treatments for patients a serious threat to human from a collaboration between IMB and Along with a diagnostic tool to rapidly with rheumatoid arthritis, inflammatory bowel health and is largely attributed Imperial College London (UK), is set to diagnose the existence of bacterial disease, and neurodegenerative disease.” to the misuse and overuse save lives and help reduce antibiotic infections, Associate Professor Coin use. Researchers have developed an is also leading a team together with PROFESSOR JENNIFER STOW, RESEARCH TEAM LEADER of antibiotics in humans and innovative new method to distinguish Professor Matt Cooper and Dr Mark intensive agricultural practices. viral and bacterial infections in children. Blaskovich to develop a powerful and portable diagnostic tool to rapidly RIGHT PROFESSOR JENNIFER STOW (CENTRE) WITH RESEARCH COLLEAGUES Associate Professor Lachlan Coin from Associate Professor Coin said bacterial DR ADAM WALL (LEFT) AND MR DARREN BROWN (RIGHT) diagnose which bacterial infection a IMB’s Centre for Superbug Solutions and viral infections could be difficult patient has contracted. said multidrug-resistant bacteria, or to tell apart. “Both types of infections Across the globe, scientists are hard at “But when the body is in a disease state It binds directly to pathogen receptors superbugs, are serious cause for can cause similar symptoms such as “Current tests leave patients and doctors work studying the processes behind the the innate immune system can not on immune cells, providing incredible concern. fever, sore throat, fatigue, vomiting and waiting 24-48 hours for a diagnosis, plethora of diseases affecting society. resolve the issue, because the triggers specificity to the inflammatory response and they do not always deliver a clear “Unless we can preserve the power of diarrhoea,” he said. What if one process was at the centre are constantly present, so it keeps that is initiated. answer,” Associate Professor Coin said. antibiotics, by 2050 superbugs could of it all? Inflammation is associated with responding. An ongoing response can “Many children around the world receive This discovery has delivered an be claiming the lives of 10 million people many, if not most, common diseases. It be very harmful.” unnecessary antibiotic treatment for viral “This uncertainty and delay in diagnosis unprecedented opportunity to manipulate each year,” he said. is triggered when the body’s defence infections, while dangerous bacterial increases the risk of the infection Inflammation can occur in specific areas inflammation, for example by turning system identifies a problem. spreading. It also leads to inappropriate “A huge part of the problem is the infections, such as meningococcal of the body, as is the case for arthritis, or off the production of specific protein antibiotic use as doctors often use a overuse and misuse of antibiotics, with disease, are missed in others.” When it works effectively, it solves it can be systemic, spreading throughout messengers called cytokines that trial and error approach to identify an the problem and protects us. When the body, in the case of sepsis. At its contribute to destructive inflammatory 50 per cent prescribed unnecessarily. The Australian Commission on Safety and antibiotic that works. it goes wrong, however, uncontrolled most extreme, as in the case of septic processes in different diseases. Quality in Health Care found antibiotic use “To minimise the overuse of unnecessary inflammation can become the driver shock, systemic inflammation can be fatal. to be particularly high in Australia, with “The diagnostic tool we are working on “We are currently characterising exactly antibiotics, researchers from the Centre for disease throughout our bodies. more than 30 million prescriptions filled in will allow clinicians to identify a patient’s Professor Sweet said inflammation is how this protein interacts with pathogen for Superbug Solutions are developing It can drive the pathology and 2014. Those most likely to be prescribed type of bacterial infection within 4-6 important to understand because it receptors. Such an understanding could a number of diagnostic tests to rapidly symptoms behind a diverse array of antibiotics are children aged 0-9 years old hours, which will allow them to rapidly is very hard to name a disease where enable us to target this protein as a identify antimicrobial resistant bacteria conditions like chronic liver disease, and the elderly. respond with the right drug, minimising inflammation is not the underlying cause new anti-inflammatory approach. This is in patients.” cancer, inflammatory bowel disease, the overuse of unnecessary antibiotics of symptoms. important because for some inflammatory Associate Professor Coin was part of cardiovascular disease, rheumatoid and preventing the spread of hospital- diseases there are no effective treatments, an international team – led by Professor arthritis, sepsis and Alzheimer’s. “The symptoms of inflammation are heat, acquired infections.” and for others, treatments are often only Levin of Imperial College London (UK) - redness, swelling and pain, which most The IMB Centre for Inflammation and effective for a sub-set of patients.” who analysed gene patterns in the blood The project was awarded $450,000 people can relate to. But inflammation Disease Research (CIDR) is identifying of children presenting with a fever at over three years in 2016 as part of the is also a driver for disease in ways that Understanding inflammation could be both the mechanisms that cause some hospitals in the United Kingdom, Queensland Government’s Advance people are less familiar with. For example, a game changer for the most common inflammation and novel ways to turn Spain, the Netherlands and the United Queensland Innovation Partnership for cancer to take hold, a tumour has to causes of death – including cancer and this process off. Could deciphering States between 2009 and 2013. funding program. Partners include grow and spread. Inflammation is a key cardiovascular disease. This discovery inflammation provide the silver bullet Children’s Health Queensland and the driver of this process. Inflammation is epitomises the innovative, fundamental “Over-prescription of antibiotics is that halts the progression of many Royal Brisbane and Women’s Hospital. similarly instrumental in other diseases. science conducted at IMB, which is significantly contributing to the rise of common diseases? changing the future of disease treatment. superbugs, so our research is a major “Being able to control inflammation could Director of CIDR Professor Matt Sweet breakthrough in this serious global IMB CENTRE FOR SUPERBUG SOLUTIONS help treat multiple diseases. Learning said the innate immune system is our challenge,” Associate Professor Coin said. DIRECTOR Professor Matt Cooper what the components of this danger IMB CENTRE FOR INFLAMMATION DEPUTY DIRECTOR Associate Professor danger response system. AND DISEASE RESEARCH Lachlan Coin response system are, and how to turn The team discovered two genes that DIRECTOR Associate Professor Matt Sweet WEBSITE superbugs.imb.uq.edu.au “The system detects when something down or turn off the system, is the focus can distinguish bacterial infection from DEPUTY DIRECTOR Associate Professor EMAIL [email protected] is wrong, becoming activated in order of our research,” said Professor Sweet. other causes of fever. Kate Schroder to respond to the danger and repair WEBSITE inflammation.imb.uq.edu.au His research team is collaborating with “Our goal is to create a portable tool for the body. Once repaired, the system EMAIL [email protected] a team led by Professor Jennifer Stow clinicians to conduct a simple blood test switches off and the body goes back to at IMB. Together they have uncovered to rapidly diagnose children and reduce normal,” he said. a protein, the first of its kind, which the incorrect and overuse of antibiotics,” is involved in triggering inflammatory Associate Professor Coin said. responses.

18 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 19 A POTENTIAL NEW PAIN DRUG DISCOVERED

“Sensory neurons transmit pain messages, and The Vetter Group is currently very for a sting to be effective, it must be painful. So excited by a venom-derived compound venomous animals and toxins have evolved to very that targets a particular protein on a nerve whose role is to signal pain. specifically target sensory neurons. To treat pain, we THE MYSTERIOUS LANGUAGE also need to be able to target sensory neurons, so “The protein is not involved in touch or OF PAIN AND THE FIGHT we’re examining the active components in venom other sensations, so this compound has exciting prospects as a pain drug. It is and toxins to see if they can teach us how to do that.” very selective, which means it doesn’t have any side effects, so we will take this further and hopefully develop a new drug,” said Dr Vetter. Within our bodies, we have an intricate network of nerve cells that help us to The group is confident that the drug perceive the world. They are called will be effective against common T O sensory neurons. Sensory neurons types of acute pain as well as a rare convert external stimuli from the and excruciating disease called environment into messages within the Man on Fire Syndrome. They are body. One of their roles is to transmit also hopeful that it will be useful in pain messages to the brain. It is a useful treating a wide variety of disease- process that protects us from damage related pain such as postherpetic SWITCH (in the case of touching a hot surface), neuralgia, diabetic neuropathy, cancer but with certain diseases, it can cause pain, and chemotherapy-induced pain. debilitating chronic pain that science is Chemotherapy induced pain for example currently at a loss to treat. occurs in more than 90 per cent of patients, can force people to stop life- The Vetter Group, led by Dr Irina saving treatment, and can be irreversible. IT Vetter, is part of IMB’s Centre for Pain Research. They are demystifying the The group is currently looking for different pathways that contribute to funding to continue their research pain in various disease states so that on the compound to explore which we can help the one in five Australians disease related pain and acute pain the that live with chronic pain. compound would be effective against. OFF The translation of this research into a “Chronic pain costs the Australian economy around $40 billion per year usable drug is a long process, but the and the global pain market continues to Vetter Group is also employing unique grow. It causes enormous disruption to pharmacological methods to repurpose people’s physical and mental wellbeing existing drugs, for more immediate and their personal life. There is also a translations into clinical practice. lot of stigma around pain because of “We have a translational capability. We the lack of understanding about its always make sure that what we find cause, and because you cannot see in a cell has meaning in an organism. pain,” said Dr Vetter. We are well placed to deliver real Current drugs either do not work or have outcomes.” terrible side effects, like addiction. But

the Vetter Group is looking to change IMB CENTRE FOR PAIN RESEARCH

that. Through biomedical research and DIRECTOR Professor Richard Lewis pharmacology, they hope to develop DEPUTY DIRECTOR Dr Irina Vetter better treatments for pain - targeted WEBSITE pain.imb.uq.edu.au EMAIL [email protected]

DAVID MULLINS, MARINE IMAGES MULLINS, DAVID treatments with no adverse side effects. They are searching for answers in what

CREDIT might seem like a peculiar place – venoms.

20 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 21 G R O W I N G NEW ORGANS

– SCIENCE FICTION OR SCIENCE FUTURE?

ABOVE MS ALISHA TROMP (LEFT) AND DR KELLY SMITH (RIGHT) RIGHT DEVELOPING ZEBRAFISH HEART AT TWO DAYS POST FERTILISATION

The demand for organ donation The focus of their research is the heart. SIX NEW GENES DISCOVERED – “When we knock this gene out in fish THE SOLUTIONS OF THE FUTURE Heart attack and cardiac arrest is the AND WHAT THEY MEAN FOR avatars, their hearts skip a beat – they increases every year, but the The value of understanding also goes biggest killer in the western world. HEART HEALTH have cardiac arrhythmias. It’s early days, tissue available for donation beyond finding a solution. Heart rhythm dysfunction affects but we might be looking at something The Smith Laboratory, which is part of remains static. Dr Kelly 5 per cent of the aged population that we could target with a drug,” Dr “We can screen foetuses for heart the University of Queensland’s Centre But with the progress being made Smith, during her PhD, was and arrhythmias 2 per cent of under Smith said. defects, and we can diagnose them. for Cardiac and Vascular Biology, by research like that of the Smith in the place where surgeons 65-year-olds. Cardiomyopathy, where We can provide parents with peace of conducts their research primarily using “Another exciting new discovery is a Laboratory, the possibility is no longer the heart becomes enlarged and thin, mind that the problem with their baby performed Australia’s first zebrafish. They create a fish version of gene that is influential in the ‘scaffold’ science fiction. is responsible for many sudden deaths. was not something they did wrong split liver transplant. a patient (an avatar) with a particular that both holds the cells of the human Congenital heart defects affect one in during pregnancy – it is genetic. We can gene mutation and monitor what is body together, and allows them to The UQ Centre for Cardiac and Vascular They were trying to get more out of 110 babies. also inform them of the risks of these happening within the embryo. communicate with each other. It’s called Biology brings together eight different the organs that they had, and Dr defects being passed on again.” “How does a heart grow? How do the the extracellular matrix, and its present research laboratories, including the Smith thought ‘we should be making Through this process, with a very large Smith Laboratory, with a focus on first cells in an embryo develop to form in all tissues and organs. “I’ve always been a fan of science fiction. these’. She had found her research sample of fish over a two-year period, research excellence in cardiac and a beating muscle that pumps blood And while I don’t think there will ever be passion. She is now leading a team of the research team and collaborators “Our bodies are made of cells that are vascular biology. Collaboratively, throughout the body?” said Dr Smith. a pill that can fix everything, I do think developmental biologists studying how screened over 400 families of fish with like bricks in a wall. The extracellular they study several different aspects once we know how things work, we will the embryo forms from a single cell to a Understanding how the first cells in an gene mutations. They found six new matrix is like the mortar that holds of cardiovascular development, find solutions to many problems.” living, functioning organism. embryo contribute to a specific organ genes whose function has never been the cells together. It also provides a regeneration and disease. and understanding how that organ described before. way for the cells to communicate with Gene editing in humans, where we develops is the first step in creating or one another. We discovered a gene go in and correct genetic errors in Dr Smith’s research team discovered a healing that organ. that makes a protein, which we think our makeup, is a long way away. We UQ CENTRE FOR CARDIAC AND gene that may be necessary for proper VASCULAR BIOLOGY degrades one particular component of first need to understand exactly what “Once we know what is causing the cardiac rhythm. CO-DIRECTORS Dr Ben Hogan (based at IMB), the matrix.” the role of every gene is and the problem, we can look at strategies for Professor Wally Thomas (based at UQ School repercussions of making any changes. of Biomedical Sciences) how to fix it.” WEBSITE cardiovascularbiology.org.au EMAIL [email protected]

22 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 23 GRANTS AND FELLOWSHIPS

GRANTS 15 NHMRC project grants totalling COMPETITIVE FUNDING FELLOWSHIPS FELLOWSHIPS COMMENCED IN 2016 $9,765,847 The quality of IMB research was represented IMB researchers are supported by 1 ARC Discovery Early Career Researcher Award (DECRA) totalling $360,000 2 NHMRC Development grants recognised by the National Health and a range of competitive fellowship 2 ARC Future Fellows totalling $1,485,684 totalling $1,938,856 Medical Research Council (NHMRC) schemes. Thanks to the support of 1 NHMRC-ARC Dementia Research Development Fellow totalling $601,958 and Australian Research Council (ARC) 15 ARC Discovery Project grants these funding organisations, IMB % 1 NHMRC Research Fellow totalling $622,655 through the award of the following grants totalling $6,513,588 Fellows have the opportunity to conduct 2 NHMRC Career Development Fellows totalling which commenced funding in 2016: 1 ARC Linkage Infrastructure, 54 valuable research with the potential to $932,831 Equipment and Facilities (LIEF) advance global scientific progress and 1 John Stocker Postdoctoral Fellow totalling $276,000 grant $840,000 improve the health and wellbeing of 1 Motor Neuron Disease Research Institute of Australia Inc Postdoctoral people around the world. Fellow totalling $330,000 of IMB’s total income in 2016 TOTAL COMPETITIVE FELLOWSHIPS CONTINUING IN 2016 1 ARC Australian Laureate Fellow 5 ARC Future Fellows 2 ARC Discovery Early Career Researcher Awards (DECRA) 14 NHMRC Research Fellows 3 NHMRC Career Development Fellows 1 NHMRC/Heart Foundation Career Development Fellow 1 The Viertel Charitable Foundation Senior Medical Research Fellowship 3 NHMRC Early Career Fellows

2016 SOURCES OF COMPETITIVE FUNDING

Australian Academy of Technology and Engineering 12% Australian Research Council Australian Tropical Medicine Commercialisation Programme 10% 27% Bill and Melinda Gates Foundation (US) Brain and Behavior Research Foundation Cancer Council Queensland 51% Commonwealth Department of Foreign Affairs & Trade Ferring Research Institute Horizon 2020 International Association for the Study of Pain Competitive Funding Sources John Stocker Postdoctoral Fellowship Motor Neurone Disease Research Institute of Australia Inc 27% ARC National Foundation for Medical Research and Innovation 51% NHMRC 10% Domestic National Health and Medical Research Council 12% International Prostate Cancer Foundation of Australia The Kids’ Cancer Project The Michael J Fox Foundation Shake It Up Australia Foundation

ABOVE PROFESSOR ROB PARTON (LEFT) AND DR TOM HALL (RIGHT)

24 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 25 AWARD HIGHLIGHTS 2016 SCIENTIST ACKNOWLEDGED FOR CONTRIBUTIONS TO PEPTIDE SCIENCE

Dr Markus Muttenthaler received the Miklós Bodanszky Award for his significant contributions to peptide-based drug research. The award was presented at the Opening Ceremony of the 34th European Peptide Symposium in Germany. Dr Muttenthaler is REPRODUCTIVE BIOLOGY RESEARCHER AWARDED FOR EXCELLENCE internationally recognised for discovering potentially therapeutic peptides in venoms. His work focuses on developing tools that Professor Peter Koopman is one of five top international researchers who were presented with a 17th Royan International Research facilitate basic fundamental research and the drug discovery Award in Reproductive Biomedicine by the Royan Institute. He received the Embryology Award for recent work on the molecular process. Dr Muttenthaler also received a Ferring Innovation genetics of sex development, fertility, gonadal cancers and intersex conditions. Winners presented a lecture at the Royan Twin Award from Ferring Research Institute Inc to further a peptide- Congress on Reproductive Biomedicine and Stem Cell Biology and Technology. based drug research project in reproductive health.

ABOVE DR REBECCA COLL BELOW DR MARKUS MUTTENTHALER YOUNG IMMUNOLOGIST AWARDED FOR IMPACT

VASCULAR BIOLOGY RESEARCHER In recognition of a discovery that could AWARDED FOR LEADERSHIP benefit patients living with inflammatory diseases, IMB early career researcher Associate Professor Ben Hogan was awarded the 2016 Emerging Dr Rebecca Coll was awarded the 2016 Leader Award from the Australia and New Zealand Society for Cell Research Australia Discovery Award. Dr and Developmental Biology (ANZSCDB). He was acknowledged Coll received her award at the Research for his leadership and accomplishment in cell and developmental Australia Health and Medical Research biology. Associate Professor Hogan’s work investigates how the Awards ceremony in Sydney for her vascular and lymphatic systems form in the embryo to develop work in identifying promising anti- better treatments for cardiovascular diseases like stroke, macular inflammatory compounds that block the degeneration, inflammation, and cancer metastasis. PRAISING WORK TOWARDS DISCOVERING NLRP3 inflammasome — a key driver of NEW ANTIBIOTICS inflammation. Dr Coll studies the immune system and how it works to control ABOVE DR JOSEPH POWELL In recognition of their efforts in fighting the battle against antimicrobial inflammation in the body. Uncontrolled resistance, IMB’s Community for Open Antimicrobial Drug Discovery (CO-ADD) inflammation contributes to the IMB SCIENTIST WINS team received an award for research at the UK Antibiotic Guardian Awards. progression of many diseases including TOP MINISTER’S AWARD CO-ADD is a global open-access screening initiative established to screen the diabetes, arthritis, cancer, multiple diverse chemical space of synthetic chemists around the world with the aim of sclerosis and neurodegenerative diseases Dr Joseph Powell was awarded the uncovering compounds with antimicrobial potential. such as Alzheimer’s and Parkinson’s. Commonwealth Health Minister’s Award for Excellence in Health and Medical Research. The prestigious award, administered by the National Health and Medical Research Council (NHMRC), recognises Dr Powell’s research ABOVE PROFESSOR KIRILL ALEXANDROV (CENTRE) WITH DR ZHONG GUO (LEFT) TOP MOLECULAR BIOLOGIST AND DR FERNANDA ELY (RIGHT) achievements in the field of statistical AWARDED RESEARCH MEDAL genomics. Dr Powell’s research uses INNOVATIVE RESEARCH TO ASSIST large-scale genomic data to investigate Associate Professor Brett Collins was awarded the the ways genetic differences in humans ORGAN TRANSPLANT PATIENTS Merck Research Medal from the Australian Society for Biochemistry and Molecular Biology (ASBMB). can affect their disease susceptibility. Professor Kirill Alexandrov’s research into developing personal The 2016 Merck Research Medal is awarded to diagnostic devices was recognised at the National Health and Dr Powell is the only Queensland an outstanding Australian biochemist or molecular Medical Research Council Research Excellence Awards. He was researcher to receive this accolade biologist with less than 15 years’ postdoctoral acknowledged for holding the top-ranked Developmental Grant in its 16-year history. The award was experience. As part of the award, Associate Professor application for his project with Molecular Warehouse Ltd (UK). presented at the Medical Research Week Collins presented at the Merck Medal Lecture at the Point-of-care test for immunosuppressant drugs. Professor Dinner hosted by the Australian Society ComBio 2016 meeting. for Medical Research in Melbourne. Alexandrov’s work aims to assist patients who have had organ transplants, by developing a test for patients and clinicians to easily LEFT DR SAROJA WEERATUNGA (LEFT) AND ASSOCIATE PROFESSOR monitor immunosuppressant drug levels which is vital to avoid BRETT COLLINS (RIGHT) organ rejection by the body.

26 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 27 LEARNING

28 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 29 RESEARCH TRAINING

“The IMB’s strong commercial and translational focus is one of the main reasons why I was interested to work there. As a postgraduate student at the IMB, I was exposed to different aspects of research commercialisation, such as obtaining patent protection, seeking funding and starting up spin-off companies based on new discoveries. I was also provided with opportunities to further develop my understanding of research commercialisation. These experiences further piqued my interest in research commercialisation and also exposed me to various roles outside of research science, including my current role as a patent attorney.”

SHEILA BARBERO, IMB PHD GRADUATE, PATENT ATTORNEY

PROVIDING A HIGH QUALITY CELEBRATING STUDENT SUCCESS In recognition of entrepreneurial ability STUDENT EXPERIENCE and skills gained through experience, An impressive 100 per cent of IMB’s training and practical application IMB is committed to providing students graduating honours students received during the course of studies at IMB, with the best possible opportunities first class honours in 2016. ten students were awarded an IMB and experiences, to ensure students PhD candidate Bruno Madio won the Entrepreneur Training Award in 2016. leave the Institute poised to create people's choice award at the UQ All- They were Kerstin Zoidl, Pengxiang Ji, lasting change in the world. IMB Institute Three-Minute-Thesis (3MT) Claudia Stocks, Sanjaya KC, Jonathan supported 162 Research Higher competition. 3MT is a multi-national Bester, Jake Parker, Clarissa Rios Rojas, Degree (RHD) students and 60 competition that cultivates students’ Eduardo Albornoz, Weili Wang, Pritesh undergraduate students during 2016. academic, presentation, and research Prasad, and Hoang-Nga Nguyen. The inquisitiveness and creative thinking communication skills. they bring to their research teams is WHERE ARE THEY NOW highly valued and no doubt contributes PhD student Georgianna Kae Oguis greatly to IMB’s success. (Craik group) won a poster prize at Many graduates have gone on to secure ComBio2016. ComBio is a major research positions at leading institutions Working in a multidisciplinary conference held annually, organised by around the world. environment with cutting-edge the Australian Society for Biochemistry technologies at their fingertips, students Dr Fabian Kurth (formerly and Molecular Biology. are offered opportunities to team up Martin group) is now Strategy and with peers, attend workshops, meet Jake Parker was one of the few Operations Lead for Briston-Myers with industry stakeholders, learn from students selected through UQ’s Idea Squibb in Germany. experienced mentors and publish Hub to participate in The China Mobility Dr Jordan Follett (formerly research findings. RHD students are also Program. This is a four-week international Teasdale Group) is now working at provided with a $2000 travel scholarship internship specialising in innovation and the Department of Medical Genetics, to present their research at a conference entrepreneurship, which is based at some University of British Columbia in within Australia or around the world. of Shanghai’s best technology start-ups. Canada. Dr Angie Jarrad (formerly Cooper Group) is now working at the Helmholtz Centre for Infection Research in Germany. Dr Julie Klint (formerly King group) is now a Research Scientist at Lundbeck in Denmark.

30 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 31 RESEARCH HIGHER DEGREE RESEARCH TRAINING AT A GLANCE DEVELOPMENT THROUGH MENTORSHIP

Students at IMB are encouraged to attend workshops and professional STUDENTS networking events to broaden their skill sets and assist them in reaching their full potential.

IMB’s Postgraduate Office organised a Joanna Akello Agwa Md. Mahadhi Hasan Sassan Rahnama 41 range of extracurricular activities and Eduardo Albornoz Balmaceda Anke Hering Vanessa Raileanu programs during 2016, including: Mubarack Abkah H. Alzubaidi James Hill Restuadi Restuadi research higher degree Oral Communication workshop Chee Wei Ang Marwa Hussain Ali Ignacio Retamal Lantadilla students graduated – facilitated by Emeritus Professor Sungmin Baek Mathilde Israel Clarissa Rios Rojas Roland Sussex OAM, this workshop Guillaume Bernard Kapil Jain John Roles % is focussed on talking science to non- Damien Bierschenk Penxiang Ji Jessica Rowley scientists, presentation skills, as well Brandon Binnie Keyi Jiang Manohar Salla 100 as lecturing and tutoring. Nayara Braga Emidio Yan Jiang Haojing Shao honours students – Lou Brillault Yuhong Jiang Shwetha Sivakaminathan received first class honours Entrepreneurship workshop Yuanzhao (Nick) Cao Wooram Jung Bronwyn Smithies arming students with the necessary Samuel Capon Irfahan Kassam Hana Starobova knowledge and skills to translate their Saskya Carrera Pacheco Sanjaya KC Maren Janina Steinbeck 121 research discoveries into potential Amy Chan Shamsunnahar Khushi Timothy Stephens inventions. Irene Chassagnon Hyun (Tom) Kim Jamie Stevens active research higher 60 UQ Idea Hub workshops – focused degree students Smrita Chaudhury Lalith Kummari Claudia Stocks on ideation, technology choices, Wenhan Chen Hyun Jae (Josh) Lee Rhia Stone prototyping, market validation and Gamma Chi Geraldine Ler Jasmin Straube Honours, undergraduate, business modelling to help progress Ivy Chiang Xuan Liang Chandra Datta Sumi occupational trainee and student projects to a prototype stage coursework masters students Chun Yuen (Jonathan) Chow Ye-Wheen Lim Li Chang Jessica Teo ready for market testing and validation. hosted at IMB Signe Christensen Emma Livingstone Samuel Tong UniQuest Research Vignesh Kartik Chundru Bruno Madio Constanza Ludovica Vallerga 30 Commercialisation workshop – all Nicholas Condon Alex McCann Felicitas Vernan different countries IMB second year students were Ben Cristofori-Armstrong Helen Mendel Dan Wang given the opportunity to participate represented in our student cohort Yi Cui Justin Mitchell Peiqi Wang in a Research Commercialisation Jason Da Silva Osama Mohamed Weili Wang Workshop, run by UniQuest, UQ's Kaustav Das Gupta Md Moniruzzaman Hongyang Wang commercialisation company. Thomas Dash Ambika Mosale Venkatesh Murthy Krishantha Pradeep Wardamune Venture capitalists extend Jessica De Angelis Alexander Mueller Gedara opportunities to IMB students to meet Darren Do Laizuman Nahar Kenneth Wee with them on a regular basis. Lilong Dong Pratik Neupane Andrew White HealthHack – a national event that Junqiao (Helen) Du Hoang-Nga Nguyen Chongyang Wu brings medical researchers, health Kinga Duszyc Hoang Son Nguyen Xiaosa Wu professionals, software developers, Mriga Dutt Georgianna Kae Oguis Yang Wu engineers, designers and students Ingrid Edwards Jeroen Overman Yeping Wu together to find solutions to important Sing yan Er Jake Parker Yue Wu “The most important thing I learned at IMB is critical health problems. Clayton Friedman Blessy Abraham Paul Dake Xiong thinking and the importance of collaboration. Professor Majbrit Froesig-Joergensen Wanida Phetsang Weijun Xu Many students participated in Emily Furlong Gregoire Philippe Angli Xue Capon taught me how to raise various hypotheses for additional workshops run by Raul Gonzalez Pech Sarah Piper Alina Zamoshnikova an experimental phenomenon, how to find potential UQ’s Graduate School, such as Daniela Grassini Miranda Pitt Qiang Zhang values from a project and explore a research topic in Communicating for impact outside Lin Grimm Kwan Yuen Eunice Poon Chenxi Zhou depth. I believe the way of thinking I learned is far more Academia. Jing Guo Pritesh Prasad Rebekah Ziegman IMB offer workshops and seminars to valuable than any skills or publications, and will promote Shafali Gupta Anggia Prasetyoputri Kerstin Zoidl support the development of students Haiou (Seagull) Qu me to be an independent scientist in the future.” for careers in academia and beyond. ALEX SHANG, IMB PHD GRADUATE

32 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 33 2016 RHD CONFERRALS

NAME SUPERVISOR DEGREE THESIS TITLE NAME SUPERVISOR DEGREE THESIS TITLE Hafiza Abdul Ghani Professor David Craik PhD Engineering cyclotides as scaffolds for peptide-based drug design Barbara Maier Professor Melissa PhD Analysis of the recreation, maintenance and differentiation of Nikita Abraham Professor Richard PhD Investigating nAChR structure and function using AChBP and Little nephron progenitors for use in disease modelling Lewis α-conotoxins Masuda Khurshied Professor Kirill Mphil Development of a novel protein biosensor technology for the early Rubbiya Ali Professor Ben PhD Developing 3D novel edge detection and particle picking tools for Nabi Alexandrov diagnosis of prostate cancer Hankamer electron tomography Daniel Nielsen Professor David Fairlie PhD Structural features in orally bioavailable cyclic peptides Yingnan Cong Professor Mark PhD Constructing genetic exchange communities among bacteria and Tae Gyu Oh Professor George PhD Understanding epigenetic signalling of nuclear receptor and Ragan archaea Muscat coregulator in breast cancer: elucidating the novel role of RORɣ, Claudio Cortes Associate Professor PhD Novel regulators of primary cilium function revealed by molecular PRMT2 and PRMT6 Rodriguez Carol Wicking studies in ciliopathies Rosa Prahl Professor Glenn King Mphil Venoms-based discovery of novel modulators of human neuronal Zhenling Cui Professor Kirill PhD Exploiting redundancy of the genetic code for site-selective α7 and α3* nicotinic acetylcholine receptors Alexandrov unnatural amino acids incorporation in vitro Reyna Michelle Professor Rob Capon PhD Microbial biodiscovery: Exploring venomous animal associated Tram Anh Do Professor David Fairlie PhD Towards new drugs for treating colitis Quezada Iniguez microbes as sources of new chemical diversity Chun-Wei Feng Professor Peter PhD Regulation of germ cell meiosis and differentiation in mice Anjaneya Swamy Professor David Craik PhD Discovery and mode of action of cyclotides Koopman Ravipati Jordan Follett Associate Professor PhD The role of retromer in Parkinson’s disease Zoe Schofield Professor Matt PhD Modulating innate immune responses through the putative anti- Rohan Teasdale Cooper inflammatory target FFA2 Dejan Gagoski Professor Kirill PhD Streamlined cell-free pipeline for production and analysis of Zhuo Shang Professor Rob Capon PhD Unveiling the chemical diversity of marine intertidal fungal Alexandrov recombinant proteins communities Joel Goode Professor George PhD Identification of the mechanisms underlying the endurance Atefeh Taharian Fard Professor Mark PhD Modelling the landscape of cellular development and disease Muscat phenotype in transgenic mice that over express the nuclear Ragan receptor, Nor-1 Wei Xuan Teo Associate Professor PhD Examining the contribution of host cell membrane trafficking Gisela Jakob Professor Ben PhD Scale-up cultivation of Australian algae New approaches to Rohan Teasdale pathways to intracellular infection biology Hankamer isolation, mid-scale cultivation and harvesting of Australian wild Vikas Tillu Professor Rob Parton PhD Structural and functional characterisation of the cavin membrane type algal strains coat complex Angie Jarrad Professor Matt PhD Novel nitroimidazole and glycopeptide antibiotics targeting enteric Zewen Tuong Professor George PhD Retinoid-related Orphan Nuclear Receptor Alpha and Cooper pathogens Muscat Macrophages in Lipid Metabolism and Immunity Prerna Jha Professor Matt PhD Structure-function studies of norepinephrine and the allosteric Darya Vanichkina Dr Cas Simons PhD Marvellous complexity: Characterising the transcriptome of the Cooper inhibitor χ-MrIA at the human norepinephrine transporter mammalian nervous system using RNA sequencing Husen Jia Professor David Craik PhD Harnessing plants to produce cyclic peptide drugs Jennifer Yarnold Professor Ben PhD Photosynthesis of microalgae in outdoor mass cultures and Prashanth Jutty Rajan Professor Richard PhD The ecology, evolution and origin of conotoxins Hankamer modelling its effects on biomass productivity for fuels, feeds and Lewis chemicals Johan Kamal Professor David Fairlie PhD Characterising Novel and Potent Modulators of Complement Jeremy Changyu Yeo Professor Jenny Stow PhD Molecular regulation of phagocytosis and signaling in Hamidon Receptor C3aR macrophages Marija Kojic Professor Brandon PhD Genetic Regulation of Development and Disorders of the Kathleen Yin Dr Irina Vetter PhD A pharmacological and transcriptomic approach to exploring novel Wainwright Cerebellum pain targets Soohyun Kwon Professor David Craik PhD Applications of sortase A in disulfide-rich peptide engineering Eugene Zhang Professor Ben PhD Enhanced microalgae growth and lipid production: a study of Hankamer cytostatic inhibitors and glycerol assimilation Chao Liu Professor Mark PhD Computational analysis of DNA repair pathways in breast cancer Ragan Pabasara Kalansuriya Professor Rob Capon PhD Microbial Chemical Diversity: Strategies to Stimulate Microbial Secondary Metabolite Potential Samuel Perry Professor David Fairlie PhD Towards cell permeable modulators of protein-protein interactions Alina Zamoshnikova Associate Professor PhD Biochemical and Functional Characterisation of NLRP12 Kate Schroder

34 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 35 ENGAGEMENT

36 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 37 4 38 patent families managed RESEARCH PARTNERSHIP 7 4 agricultural/industrial biotechnology 21 Partnership and collaboration 7 diagnostic/devices COMMERCIALISATION drive the research agenda of 6 6 drug discovery tools the IMB. Innovation cannot 21 therapeutics occur without discovery and IMB researchers are working with clinicians, industry partners and government 9 agencies in order to use life 7 sciences research to find new active Australian Research Council Linkage Projects answers to old problems. new patents filed

We welcome and invite enquiry through our Partnership and Engagement Office:

Associate Professor Carol Wicking Manager, Strategic Research Engagement % +61 409 546 968 8 > [email protected] new industry partnerships 5 formed in 2016 of IMB's publications include Dr Peter Wilson industry collaborations Research Partnership Manager IMB spinout Inflazome Ltd +61 7 3346 2194 ABOVE DR AVRIL ROBERTSON attracted up to [email protected] IMB is a partner $ IMB SPINOUT RAISES UP TO $22M 22M in the ARC Training Centre for Biopharmaceutical Innovation in Series A financing Researchers at IMB have been working IMB is pursuing commercial The intellectual property is based on OUR COMMITMENT to uncover what triggers the persistent opportunities to produce work by IMB researchers Professor TO DELIVER inflammation in the body that has Matt Cooper, Associate Professor Kate treatments to combat been linked to many diseases such Schroder, Dr Rebecca Coll and Dr IMB works closely with The University Industry partners as Alzheimers, type-two diabetes, inflammatory diseases such as Avril Robertson; in collaboration with of Queensland’s commercialisation hailed from around the globe Parkinson’s disease and arthritis. Their arthritis, asthma, Parkinson’s, Professor Luke O’Neill at Trinity College company, UniQuest, to translate our discoveries have led to the formation of Dublin, Ireland. research discoveries for disease Alzheimer’s and MS. USA UK Switzerland Ireland a new Company to develop treatments applications and sustainable futures. Inflazome Ltd is just one example of for inflammatory diseases. The potential for a small molecule Korea Netherlands Denmark how the commercialisation of IMB Together with UniQuest, IMB’s research inhibitor of this target is extremely Inflazome Ltd, the new Company research is addressing global teams are pursuing commercial promising, and over the next few years, headquartered in Ireland, raised up to health challenges. opportunities in the following areas: the Company is working to progress this A$22 million in Series A financing in research to clinical trials. Human therapeutics – including new 2016, one of the largest biotech Series treatments for inflammation, pain, A investments for intellectual property The multi-million dollar investment metabolic disorders, infection and originating from an Australian university. means that Inflazome can develop new cancer; drug candidates for millions of people Inflazome Ltd is developing treatments Agriculture – including insecticides, around the world who are affected by by inhibiting the inflammasome, a key and pesticides; and inflammatory diseases. IMB spinout Protagonist was listed on the NASDAQ in 2016, raising biological pathway associated with Biotechnology – including a wide variety of diseases driven by microalgae-based biofuels and chronic inflammation. production of high-value materials. AU$118M in its initial public offering, and awarded Australian Company of the Year

38 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 39 COMMUNITY SUPERBUGS AT THE OLYMPICS Following the 2016 Olympic Games, IMB’s Centre for Superbug Solutions hosted a community event to discuss the health threat posed by superbug-infested waters during the Olympic Games in Rio. Held during Antibiotic Awareness ENGAGEMENT Week in November, attendees heard from various sport and science experts. Speakers included bacterial sepsis survivor and Rio 2016 gold medalist Paralympian Chris Bond OAM, Rio Olympic rower Fiona Albert, IMB superbugs researcher WORLD SCIENCE FESTIVAL INFLAMMATION SYMPOSIUM Dr Mark Blaskovich and Triathlon Australia Chief Medical Officer Dr Mark Young. Professor Jennifer Stow presented a talk at the World Science IMB’s Centre for Inflammation and Disease Research LEFT ASSOCIATE PROFESSOR LACHLAN COIN Festival held in Brisbane. As part of her presentation, titled hosted a one-day inflammation symposium for research Finding beauty in the breakdown: looking through the lens at students, postdoctoral staff and senior researchers disease, Professor Stow showcased fantastic images created around Australia. The goal of the symposium is by members of her research group. She also discussed the to provide scientific discussion and networking BRAINCHILD FOUNDATION advanced imaging techniques available today that allow us opportunities. Clinicians and researchers were able RESEARCH INFORMATION EVENING SCIENCE IN THE CINEMA to watch the visual stories of our living cells unfold before our to develop new collaborations and partnerships in Together with the Brainchild Foundation, IMB participated eyes with remarkable and unprecedented detail. inflammation research. Researchers from IMB’s Centre for Pain Research in a research information evening at Customs House in participated in an expert panel discussion as part May. Professor Brandon Wainwright was a guest speaker of The Australian Society for Medical Research’s during the evening, which was held to showcase the work Science in the Cinema event. IMB’s Professor Glenn of researchers supported by the Foundation. Guests King and Dr Irina Vetter spoke about their chronic heard about the research progress that has been made pain research and future treatment options following PAIN: MAKING IT PERSONAL to date, and how Brainchild Foundation’s generous grants a screening of the film CAKE, a true-life drama about are assisting researchers in the field of childhood brain Scientists from IMB’s Centre for Pain Research joined leading a chronic pain sufferer and how her pain and grief tumours. Brainchild founder and Brisbane neurosurgeon clinical pain scientist, Professor Lorimer Moseley and Chronic affected her behavior, relationships, and her ability to Dr Martin Wood was a key speaker during the evening. Pain Australia President, Dr Coralie Wales, for a community function in day-to-day life. seminar held during National Pain Week. The speakers BELOW BRAINCHILD FOUNDER AND NEUROSURGEON DR MARTIN WOOD provided guests with a fascinating insight into the challenging and personal nature of pain management, and how it is inspiring a new generation of patient-focused treatments for one of the most poorly understood and undertreated conditions in modern medicine. TRANSLATING GENOMIC DATA INTO

RIGHT PANEL MEMBERS AT IMB'S PAIN: MAKING IT PERSONAL EVENT. (LEFT TO RIGHT) CANCER TREATMENTS DR JENNIFER DEUIS, PROFESSOR LORIMER MOSELEY, DR CORALIE WALES, PROFESSOR RICHARD LEWIS, DR IRINA VETTER. Professor Brandon Wainwright presented a talk to staff at Lady Cilento Children’s Hospital’s Oncology Services Unit, titled the challenges of converting genomic information to new therapeutics for medulloblastoma. IMB researchers are working with clinicians across the State and nationally to find treatments THE PHARMA REVOLUTION: for cancers, rare diseases, Motor Neurone Disease (MND), GROWING MEDICINAL heart and lung diseases. DRUGS IN YOUR BACKYARD

IMB’s Professor David Craik and Dr Sónia Henriques gave a fascinating presentation at the UQ Global Leadership Series about their work on growing 3RD ANNUAL QUEENSLAND FORUM ON ANTIMICROBIAL RESISTANCE medicines in plants. Guests heard how Clinicians and researchers gathered at a forum to focus on a One Health approach to fighting antimicrobial cancer could one day be treated by resistance. They were given the opportunity to share ideas, build new collaborations and promote closer ties drinking tea, chronic pain controlled between academic researchers, clinicians and industry partners. by swallowing sunflower seeds and obesity cured by eating fries made from Guests included experts in infectious disease, microbiology, diagnostics, epidemiology, pharmacology, genetically engineered potatoes. medicinal chemistry, agriculture and veterinary sciences. Held at the Royal Brisbane and Women's Hospital, the forum was hosted by IMB's Centre for Superbug Solutions, in collaboration with Queensland Health's CLOCKWISE DR SÓNIA HENRIQUES, PROFESSOR BRANDON WAINWRIGHT AND PROFESSOR DAVID CRAIK Communicable Diseases Clinical Network and Queensland Statewide Antimicrobial Stewardship Program. PROFESSOR DAVID CRAIK AND DR SÓNIA HENRIQUES SPEAKING AT THE UQ GLOBAL LEADERSHIP SERIES GUESTS AT THE UQ GLOBAL LEADERSHIP SERIES

40 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 41 IMB GLOBAL COLLABORATIONS 2016 GLOBAL COLLABORATIONS

IMB connected with industry, education, government and clinical partners around the globe to share knowledge and work together to progress research towards significant healthcare outcomes for patients.

Australia Hungary Philippines Austria Iceland Poland Bahrain India Portugal Belgium Indonesia Qatar Brazil Iran, Islamic Republic of Romania Canada Ireland Russian Federation Chile Israel Saudi Arabia China Italy Serbia Colombia Jamaica Singapore Croatia Japan Slovenia Czech Republic Korea, Republic of Spain Denmark Lebanon Sri Lanka Egypt Macao Sweden Estonia Malaysia Switzerland Finland Netherlands Taiwan, Province of China France New Zealand Thailand Germany Nigeria Turkey Greece Norway United Kingdom Hong Kong Pakistan United States

42 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 43 OUR PEOPLE

44 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 45 LIST OF MEMBERS OF BOARDS AND COMMITTEES

ADVISORY BOARD Professor Robyn Ward (Mar-Sep) STRATEGIC MANAGEMENT Deputy Vice-Chancellor (Research), COMMITTEE Professor Aidan Byrne (Oct-Dec) The University of Queensland Provost & Senior Vice-President, The Dr Mark Ashton University of Queensland Dr Jane Wilson Executive Director, Intellectual Property Guardian, Future Fund Commercialisation, UniQuest Mr Bob Christiansen Deputy Chancellor, The University Managing Director, Southern Cross Dr Jodi Clyde-Smith (Sept-Dec) of Queensland Venture Partners Deputy Director (Operations and Strategy) Director of Sonic Healthcare and Professor John W Funder AC General Sir John Monash Foundation Professor Matt Cooper Senior Fellow, Hudson Institute of Director, Centre for Superbug Solutions Medical Research TRANSLATIONAL SUB-COMMITTEE Professor David Fairlie Professor, Department of Medicine, ABOVE ALEXANDROV GROUP Dr Mark Ashton Head, Chemistry and Structural Biology Monash University Executive Director, Intellectual Property Professorial Associate, Centre for Professor Ben Hankamer Commercialisation, UniQuest Neuroscience, The University of Director, Centre for Solar Biotechnology Melbourne Professor Rob Capon Associate Professor Ben Hogan Honorary Professor, Institute of IMB Group Leader, Postgraduate Co-Director, UQ Centre for Cardiac and Molecular Biosciences, The University Coordinator OUR Vascular Biology Co-Head, Genomics of Queensland Mr Bob Christiansen (Chair) of Development and Disease PEOPLE Dr Anand Gautam Managing Director, Southern Cross Professor Richard Lewis Senior Director, R&D Innovation Venture Partners Director, Centre for Pain Research Sourcing, Novo Nordisk RESEARCH STAFF Dr Cherrell Hirst AO Professor Grant Montgomery Alewood group: Paul Alewood (Group Dr Cherrell Hirst AO (Chair) Director of Medibank Private, Gold Alysha Elliott, Alejandra Gallardo- Francois group: Frank Fontaine, Director, UQ Project Three Billion leader), Andreas Brust, Zoltan Dekan, Director of Medibank Private, Gold Coast Health and Hospital Service, and Godoy, Karl Hansford, Geraldine Emmanuelle Frampton, Mathias Jean Jin, Vincent Lavergne, Markus Kaeslin, Angela Kavanagh, Ruth Neale, Francois (Group leader), Cathy Pichol- Coast Health and Hospital Service, and RSL Care Ms Maureen O’Shea Muttenthaler, Jingjing Wan Ruby Pelingon, Soumya Ramu, Janet Thievend, Renae Skoczylas RSL Care Director of Advancement Mr Andy Jane Reid, Avril Robertson, Zoe Schofield, Alexandrov group: Kirill Alexandrov Hankamer group: Ben Hankamer Professor Max Lu (Jan-Mar) Managing Director, Life Sciences, Professor Mark Ragan Danielle Sutherland, Robin Trauer, (Group leader), Zhenling Cui, (Group leader), Michael Landsberg, Provost & Senior Vice-President, The Talu Ventures Co-Head, Genomics of Development Daniel Watterson, Nicole Wheatley, Zyta Selvakumar Edwardraja, Fernanda Ely, Melanie Oey, Ian Ross, Rosalba University of Queensland and Disease Ziora, Johannes Zuegg Associate Professor Kate Schroder Dejan Gagoski, Zhong Guo, Wayne Rothnagel, Evan Stephens, Juliane Wolf Associate Professor Beverley IMB Group Leader, Deputy Director Professor Jennifer Stow Johnston, Shayli Moradi, Sergey Craik group: Hadi Ahmad Fuaad, Hogan group: Neil Bower, Jun Chen, Rowbotham of IMB Centre for Inflammation and Deputy Director (Research) Mureev, Marinna Nilsson, Patricia Angeline Chan, Olivier Cheneval, Kylie Georgas, Ben Hogan (Co- Director of Haematology at Sullivan Disease Research Walden David Craik (Group leader), Thomas Associate Professor Matt Sweet division head and group leader), Kaska Nicolaides Pathology Durek, Edward Gilding, Peta Harvey, Ms Brigitte Smith Director, Centre for Inflammation and Capon group: Rob Capon (Group Koltowska, Anne Lagendijk, Scott Part of the Sonic Healthcare group Crystal Huang, Mark Jackson, Quentin Co-founder and Managing Partner, Disease Research leader), Lea Indjein, Venkatanambi Paterson Associate Professor of Cellular and Kaas, Annie Kan, Nicole Lawrence, GBS Venture Partners Kamalakkannan, Zeinab Khalil, Angela Molecular Pathology, The University Aaron Poth, Tina Schroeder, Joakim Raveendra Anangi, Dr Ian Taylor (Jan-Aug) Salim, Sean Xiao King group: of Queensland Professor Jennifer Stow Deputy Director (Operations) Swedberg, Sonia Troeira Henriques, Yanni Chin, Evelyne Deplazes, Maggie IMB Deputy Director (Research) Minh Cao, Lachlan Coin Conan Wang, Joachim Weidmann Professor Stephen Walker Coin group: Hardy, Volker Herzig, Glenn King Professor Brandon Wainwright (Group leader), Devika Ganesamoorthy Executive Dean, Faculty of Science, (Group leader), Linlin Ma, Sandy Pineda Professor Brandon Wainwright Director Fairlie group: Aline Dantas De Araujo, Gonzalez, Lachlan Rash, Natalie Saez, The University of Queensland IMB Director Collins group: Brett Collins (Group David Fairlie (Division head and group Sebastian Senff, Jennifer Smith, Eivind Associate Professor Carol Wicking leader), Rajesh Ghai, Natalya Leneva, leader), Rebecca Fitzsimmons, Maria Undheim, Andrew Walker Director, Centre for Rare Diseases Suzanne Norwood, Saroja Weeratunga Greenup, Tim Hill, Huy Hoang, Abishek Research Iyer, Woan Mei Kok, James Lim, Ligong Koopman group: Peter Koopman Cooper group: Maite Amado, Mark Liu, Ken Loh, Rink-Jan Lohman, Jeffrey (Group leader), Ee Ting Ng, Liang Zhao Professor Alpha Yap Blaskovich, Mark Butler, Matthew Mak, Robert Reid, Nick Shepherd, Head, Cell Biology and Molecular Cooper (Group leader), Daniel Croker, Jacky Suen, Chongyang Wu, Kai-Chen Medicine Mathilde Desselle, David Edwards, Wu, Annika Yau

46 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 47 Lewis group: Asa Andersson, Fernanda Smythe group: Gregory Bourne, Caldas Cardoso, Jean Giacomotto, Christina Kulis, Jaimee McMahon, Richard Lewis (Group leader), Mark Smythe (Group leader), Adam Hoshyar Mohialdeen, Thea Monks, Stephenson, Jenny Zhang Lotten Ragnarsson-McGrath, Silmara Smith group: Jason Da Silva, Daniela Rodrigues De Sousa, Himaya Siddhihalu Grassini, Angela Jeanes, Kelly Smith Wickrama Hewage, Josh Wingerd (Group leader), Alisha Tromp Martin group: Michelle Christie, Stow group: Darren Brown, Tatiana Camila Cotrim, Shu-Hong Hu, Russell Khromykh, Lin Luo, Jennifer Stow Jarrott, Jenny Martin (Group leader), (Group leader), Adam Wall Roisin McMahon Sweet group: Ronan Kapetanovic, Montgomery group: Jenny Fung, Divya Ramnath, Melanie Shakespear, Grant Montgomery (Group leader) Matt Sweet (Group leader) Muscat group: George Muscat (Group Teasdale group: Markus Kerr, Xiaying leader), Tae Oh, Mary Wang ABOVE CAPON GROUP Qi, Rohan Teasdale (Group leader), ABOVE STOW GROUP Palpant group: Han Chiu, Nathan Zhe Yang Palpant (Group leader) Visscher: Kathryn Kemper, Luke Parton group: Nicholas Ariotti, Michele Lloyd-Jones, Allan McRae, Matthew Bastiani, Charles Ferguson, Tom Hall, Robinson, Peter Visscher (Group SUPPORT STAFF Information technology: Matthew Dominic Hunter, Harriet Lo, Nick Martel, leader), Loic Yengo Dimbou Bryant, Lyndon Cook, Christian De Administration support: Sue Allen, Kerrie-Ann McMahon, Susan Nixon, Marco, Brett Dunsmore (Manager), Vetter group: Jennifer Deuis, Irina Lucinda Essery, Katrina Garner-Moore, Robert Parton (Group leader), James Rae Calvin Evans, Nelson Marques, Lance Vetter (Group leader) Gail Howard, Patricia Howarth, Barbara Rathbone, Yves St-Onge, Jimmy Wu Powell group: Jenny Fung, Alex Synak, Deirdre Timo Wainwright group: Christelle Adolphe, Holloway, Rebecca Lim, Luke Lloyd- Infrastructure support: Kristie Laura Genovesi, Marija Kojic, Amanda Advancement: Maureen O’Shea Jones, Sam Lukowski, Quan Nguyen, Barclay, Chris Barnett (Manager), Millar, Gayle Petersen, Brandon Wainwright (Director) Joseph Powell (Group leader), Anne Jill Bradley, Tim Bruxner, Karl Byriel, (IMB Director and Group leader) Angelika Christ, Christine Fraser, John Senabouth, Peter Smartt, Emily Wong Central sterilising facility: Sol Griffin, Jacky (Chung-Wei) Hung, Alun (visiting), Chloe Yap Waters group: Yash Chhabra, Michael Koppmann, Dawn Walsh (Manager) Jones, Miki Miyagi, Darren Paul, Alan Waters (Group leader) Ragan group: Cheong Xin Chan, Alain- Commercialisation team: Mark Robertson, James Springfield Dominique Gorse, Huanle Liu, Mark Wicking group: Maria Rondon, Carol Ashton* (Manager), Yvonne Booth*, Ian Taylor (outgoing ABOVE HOGAN GROUP Ragan (Co-division head and group Wicking (Group leader) Stephen Earl*, Kylie Ellis*, Peter Wilson Operations: Director), Jodi Clyde-Smith (incoming leader), Sriganesh Srihari, Lanna Wong *Employed by UniQuest Wray: Earlene Ashton, Beben Director) Schroder group: Dave Boucher, Benyamin, Jolene Berry, Marie-Jo Communications: Bronwyn Adams, Postgraduate office: Amanda Kaiwen Chen, Rebecca Coll, Jennifer Brion, Enda Byrne, Fleur Garton, Jake Aimee Parker, Kate Sullivan, Gemma Carozzi, Olga Chaourova, Cody Dou, Caroline Holley, Mercedes Maria Gratten, Anjali Henders, Tiana McLaren, Ward Mudgway Monteleone, Kate Schroder (Group Emily Thomson, Maciej Trzaskowski, leader) External relations: Melanie Gray Anna Vinkhuyzen, Leanne Wallace, Safety manager: Paul Lovelock, Naomi Wray (Group leader), Hasti Gregory Baillie, Finance: Robyn Craik, Angela Gardner Simons group: Stores: Bob Allen, Mark McDade, Ziaimatin (Manager), Louise Hendriks, Sanjay Stephen Bent, Joanna Crawford, Cas Barry Pitt (Manager) Sundarlal Simons (IMB Fellow), Douglas Stetner Yap group: Bipul Acharya, Srikanth QFAB Bioinformatics: Anne Bernard, Budnar, Guillermo Gomez, Tatiana Grants officer: Michelle Foley Khromykh, Vanessa Tomatis, Suzie Pierre-Alain Chaumeil, Xin-Yi Chua, Verma, Alpha Yap (Division head and Human resources: Fiona Davis, Dominique Gorse (CEO), Anne Kunert, group leader) Caraine Gomez, Felicity Ray (Manager) Nicholas Rhodes, Justin Scott, Michael Thang Yang: Ting Qi, Jian Yang (Group leader), IMB Biomathematics: Nick Hamilton, Futao Zhang, Zhihong Zhu, Jian Zeng James Lefevre Workshop and maintenance: Gary Carloss, Jason Hurst, Leigh Rose, John ABOVE VETTER GROUP Srnka, Mick Thwaite (Manager)

48 IMB YEAR IN REVIEW * Research and support staff information has been taken from the 2016 UQ Staff Census as at March 2016 IMB YEAR IN REVIEW 49 JOINT APPOINTMENTS AND AFFILIATES

Joint appointments and affiliates foster research collaborations Dr Andrew Brooks between IMB and other institutes and schools at The University Diamantina Institute of Queensland and around the world. Partners are actively Professor Matthew Brown THANK YOU TO OUR 2016 involved in sharing resources and facilities, supervising students Diamantina Institute and supporting IMB initiatives. Dr Richard Clark School of Biomedical Sciences SCIENCE AMBASSADORS UQ JOINT APPOINTMENTS Dr Cherrell Hirst AO Professor Ian Frazer Director of Medibank Private, Gold Professor Kirill Alexandrov Translational Research Institute Coast Health and Hospital Service, Australian Institute for Bioengineering Associate Professor Bryan Fry and RSL Care and Nanotechnology School of Biological Sciences Professor Wanjin Hong Professor Philip Hugenholtz Professor Elizabeth Gillam Institute of Molecular and Cell Biology School of Chemistry and Molecular School of Chemistry and Molecular The IMB Science Ambassadors are a group of early-career researchers who are passionate about Biosciences Professor David Hume Biosciences The Roslin Institute science communication. They are chosen to represent the Institute at events, such as the IMB Dr Allan McRae Associate Professor Stuart Kellie Open Day and various community events held throughout the year. Ambassadors also share their Queensland Brain Institute Dr Gary Leong School of Chemistry and Molecular knowledge and enthusiasm about IMB research with donors; students; and industry, clinical and Professor Grant Montgomery Professor Yingrui Li Biosciences academic partners, when they lead tours through the Institute. Queensland Brain Institute BGI Tech Solutions Professor Bostjan Kobe Dr Joseph Powell Professor Melissa Little School of Chemistry and Molecular Queensland Brain Institute Murdoch Childrens Research Institute Biosciences Angie Jarrad (Cooper group) Abishek Iyer (Fairlie group) Claudia Stocks (Sweet group) Professor Peter Visscher Professor John Mattick AO Dr Hong Lee Queensland Brain Institute Garvan Institute Queensland Brain Institute Nikita Abraham (Lewis group) Mriga Dutt (Lewis group) Ed Gilding (Craik group)

Professor Naomi Wray Dr Wim Meutermans Professor Alan Mark Christina Schroeder (Craik group) Dejan Gagoski (Alexandrov group) James Hill (Cooper group) Queensland Brain Institute Audeo Oncology School of Chemistry and Molecular Biosciences Prashanth Jutty Rajan (Lewis group) Guillaume Bernard (Ragan group) Rink-Jan Lohman (Fairlie group) Professor Jian Yang Professor Nicos Nicola Queensland Brain Institute Walter and Eliza Hall Institute Dr Mehdi Mobli Guillermo Gomez (Yap group) Natalie Saez (King group) Avril Robertson (Cooper group) of Medical Research Centre for Advanced Imaging Atefeh Taharian Fard (Ragan group) Lou Brillault (Hankamer group) Emma Livingstone (Martin/Collins HONORARY AND ADJUNCT Dr John Pearson Dr Zoltan Neufeld group) APPOINTMENTS Marija Kojic (Wainwright group) Alan Robertson (Coin group) QIMR Berghofer Medical Research School of Mathematics and Physics Lin Luo (Stow group) Associate Professor Timothy Bailey Institute Dr Johan Rosengren Melanie Oey (Hankamer group) Sarah Piper (King group) University of Nevada, Reno Mr Ken Roberts School of Biomedical Sciences Ambika Murthy (Sweet group) Daniela Grassini (Smith group) Michelle Christie (Martin group) Former Managing Director of Wellcome Dr Peter Beattie Associate Professor Joseph Miranda Pitt (Cooper group) Former Premier of Queensland Australasia Limited Rothnagel Jessica De Angelis (Smith group) Jeroen Overman (Francois group) School of Chemistry and Molecular Christina Kulis (Smythe group) Professor Frances Brodsky Professor Peter Turnbull Juliane Wolf (Hankamer group) Melanie Shakespear (Sweet group) Biosciences University of California, San Francisco QFAB Bioinformatics Annie Kan (Craik group) Mathilde Desselle (Cooper group) Ben Cristofori-Armstrong (King group) Dr Nicola Waddell Professor Maree Smith Mr Bob Christiansen (Craik group) Tetra Q Mark Jackson Southern Cross Venture Partners Pty Ltd QIMR Berghofer Medical Research Emily Furlong (Martin group) Institute Dr Kate Stacey Dr Norelle Daly School of Chemistry and Molecular James Cook University Dr Andrew Whitten Australian Nuclear Science and Biosciences Dr Melissa Davis Technology Organisation Associate Professor Peter Thorn The University of Melbourne Professor Marino Zerial School of Biomedical Sciences Professor John Funder AO Max Planck Institute of Molecular Professor Istvan Toth Hudson Institute of Medical Research Cell Biology and Genetics School of Chemistry and Molecular Professor Frank Gannon Biosciences QIMR Berghofer Medical Research UQ AFFILIATES Associate Professor Christine Wells Institute Dr Antje Blumenthal Australian Institute for Bioengineering Diamantina Institute and Nanotechnology

Dr Mikael Boden Professor Paul Young School of Chemistry and Molecular School of Chemistry and Molecular Biosciences Biosciences 50 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 51 SUPPORTING INFORMATION

52 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 53 FINANCIAL STATEMENT IMB INCOME AND EXPENDITURE AT A GLANCE

$ INCOME 2014 $’000 2015 $’000 2016 $’000 1M $5.8M $5M $3.6M Peer Reviewed Income $5.3M ARC Grants 7,3 55 7,814 8,339 $4.3M

NHMRC Grants 18,843 16,327 15,625 $20.1M $30.1M $ State Government Grants 1,035 356 59 $14.5M 44.2M Other Peer Reviewed Grants – Domestic 3,735 1,753 2,951 Other Peer Reviewed Grants – International 914 3,523 3,715 Operating Income UQ Awarded Grants 3,571 3,377 5,296 Total income Operating (core) income Distribution of expenditure UQ Operating Funding 9,419 14,221 14,578 54% Peer reviewed (competitive) funding 25% UQ awarded grants 76% Research State Government Grants 5,000 0 0 37% Operating 70% UQ operating funding 8% Infrastructure Sales and Services Revenue 2,554 1,730 1,027 9% Philanthropy, commercialisation, 5% Sales and services revenue 6% Administration other income and recoveries 10% Capital equipment Other Income Philanthropy 309 335 379 Commercialisation 2,761 2,293 2,938 Other Income & Recoveries 835 905 1,769 Total Income 56,330 52,634 56,676 RESEARCH GRANTS

NEWLY AWARDED GRANTS COMMENCING IN 2016 TOTALLED $37,545,292.

EXPENDITURE 2014 $’000 2015 $’000 2016 $’000 IMB researchers are indicated in bold. Remuneration Expenditure TOTAL Researchers 33,635 28,351 29,385 GRANTING BODY INVESTIGATORS PROJECT TITLE DURATION GRANT Infrastructure 2,879 2,819 2,794 ARC Discovery ALEWOOD, Paul F Novel cysteine-rich 3 years $210,000 Administrative 2,242 2,475 2,975 Projects conotoxin frameworks from Research Expenditure Australian cone snails Research Services 15,356 12,534 12,571 ARC Discovery LEWIS, Richard J; ALEWOOD, Paul F & Structure and function of 3 years $469,986 Commercialisation 35 26 44 Projects DUTERTRE, S. predatory and defensive venoms in cone snails Research Higher Degree Support 1,563 1,149 1,476 ARC Discovery FAIRLIE, David Engineering peptides into 3 years $534,602 UQ Internal Collaborations and Agreements 820 950 719 Projects superglues selective for Operating Expense target proteins Capital Equipment 2,355 2,735 5,832 ARC Discovery SCHRODER, Kate A molecular timer for 4 years $494,400 Information Technology 749 606 535 Projects inflammation and cell death Administration and Support 409 496 620 ARC Discovery KOOPMAN, Peter A Systems analysis of a 3 years $399,100 Infrastructure and Development 857 950 1,000 Projects critical regulatory hub in sex determination Total Operating Expenditure 60,899 53,093 57,950 ARC Discovery ALEXANDROV, Kirill; STEIN, Viktor & GUO, Engineering electrochemical 4 years $650,300 Net Surplus/(Deficit) (4,569) (459) (1,274) Projects Zhong protein biosensors ARC Discovery COLLINS, Brett M The endosome at atomic 4 years $438,100 Projects resolution ARC Discovery TEASDALE, Rohan D Defining the membrane 4 years $468,100 Projects protein cargo transported by Retromer

54 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 55 TOTAL TOTAL GRANTING BODY INVESTIGATORS PROJECT TITLE DURATION GRANTING BODY INVESTIGATORS PROJECT TITLE DURATION GRANT GRANT ARC Discovery KING, Glenn F; UNDHEIM, Eivind A B & Unravelling the molecular 3 years $320,700 Australian BLUMENTHAL, Antje & CAPON, Robert Developing new antibiotics 3 years $275,000 Projects JENNER, R. diversity and evolution of Tropical Medicine to treat tuberculosis centipede venoms Commercialisation ARC Discovery KING, Glenn F & WALLACE, B. Voltage-dependent 3 years $435,700 Programme Projects structural changes in Bill & Melinda Gates ALEXANDROV, Kiril Repurposing glucose 2 years $133,511 voltage-gated sodium Foundation monitoring technology for channels DNA dectection ARC Discovery HANKAMER, Benjamin; STAHLBERG, H. & Molecular Resolution 3D 3 years $584,800 Brain and GRATTEN, Jake Genomic Analysis of Sex 2 years $82,354 Projects HIPPLER, M. Atlas of the Photosynthetic Behavior Research Differences in Prevalence of Machinery Foundation Psychiatric Disorders ARC Discovery SMYTH, Ian; HAMILTON, Nicholas & Morphological development 3 years $488,100 Cancer Council MUSCAT, George E; CLYNE, C.; DOWNES, Elucidating the role of the 2 years $200,000 Projects HENKELMAN RM of the kidney - a paradigm Queensland M.; CLARKE, C.; DRAY, Eloise & GALLEGO nuclear hormone receptor for organogenesis Ortega, D. RORy1 in breast cancer ARC Discovery MARTIN, Jennifer; CHOUDURY, Structure and function of 4 years $497,400 Cancer Council FRANCOIS, Mathias & HOGAN, Benjamin SOX18-VEGF cross- 2 years $200,000 Projects HASSANAL; DREW, David; ROBINSON, Carol human zinc transporter Queensland regulation during membrane proteins angiogenesis and blood ARC Discovery ROBINSON, Matthew & VISSCHER, Peter The genetics of ageing in 3 years $361,900 vascular development Projects human populations Commonwealth COOPER, Matthew & BLASKOVICH, Mark Community for Open 1 year $7,150 ARC Discovery VISSCHER, Peter Phenotypic profiling from 3 years $328,700 Department of A Antimicrobial Drug Discovery Projects DNA using genetic and Foreign Affairs & (CO-ADD) Indonesian epigenetic information Trade Engagement Program ARC Discovery YANG, Jian & GODDARD M The role of X-chromosome 4 years $319,800 Ferring Research MUTTENTHALER, Markus & BRIERLEY, S Mapping the location and 1 year $186,213 Projects inactivation in quantitative Institute function of oxytocin and trait variation vasopressin receptors throughout the gut ARC Discovery GODDARD M & YANG, Jian The extent, causes and 3 years $338,300 Projects implications of pleiotropy Horizon 2020 HÉNRIQUES, Sonia Research and Innovation 4 years $26,831 among complex traits Staff Exchange (RISE) – INPACT project ARC Discovery UNDHEIM, Eivind Unravelling the structural 3 years $360,000 Early Career evolution of centipede toxins International VETTER, Irina & DID-HAJI Sulayman The role of Nav 1.6 in 1 year $19,643 Researcher Award Association for the peripheral pain pathways Study of Pain ARC Future Fellow GOMEZ, Guillermo The mechanochemical basis 4 years $680,524 of cell polarity John Stocker HANKAMER, Benjamin; YARNOLD, Engineering photosynthesis 3 years $276,000 Postdoctoral Jennifer E & RALPH, P. for sustainable food, fuels ARC Future Fellow SCHROEDER, Christina The potential of membranes 4 years $805,160 Fellowship and chemicals - peptide engineering to modulate ion channels Motor Neurone GARTON, Fleur MND Postdoctotral 1 year $110,000 Disease Research Fellowship – To identify ARC Industrial MAHLER, Stephen M; ALEXANDROV, Kirill; ARC Training Centre 5 years $4,340,802 Institute of Australia novel genetic loci and Transformation BARNARD, Ross T; FRANCOIS, Mathias; for Biopharmaceutical Inc pathways associated with Training Centres GRAY, Peter P; HODSON, Mark P; HOU, Jeff; Innovation ALS through interrogation HOWARD, Christopher B; JONES, Martina L; of multiple integrated LUA, Linda H; OSBORNE, Geoffrey; SCHULZ, genomics data sets Benjamin L; YOUNG, Paul R & others National Foundation SMYTHE, Mark L & KULIS, Christina The Development of 1 year $80,078 ARC Linkage CRAIK, David J; DALY, N.; WILLIAMS, Craig A nuclear magnetic 1 year $840,000 for Medical Human Hematopoietic Infrastructure, M; FAIRLIE, David; BURN, Paul; MOBLI, resonance facility for Research and Prostaglandin D2 Synthase Equipment and Mohammadmehdi; LOUKAS, A. & LOPATA, A. modern molecular analysis Innovation Inhibitors (HPGD2S) For Facilities Allergic Asthma Australian Academy BLASKOVICH, Mark A Global Connections Fund 1 year $7,000 NHMRC Career POWELL, Joseph Control of genome 4 years $469,180 of Technology and Priming Grant: Antibody- Development regulation and its role in Engineering antibiotic conjugates to treat Fellowship human disease drug-resistant bacteria NHMRC Career FRANCOIS, Mathias Decoding the transcriptional 4 years $463,652 Development program of vessel growth in Fellowship health and disease

56 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 57 TOTAL TOTAL GRANTING BODY INVESTIGATORS PROJECT TITLE DURATION GRANTING BODY INVESTIGATORS PROJECT TITLE DURATION GRANT GRANT NHMRC-ARC GHAI, Rajesh Towards targeting 4 years $601,958 NHMRC Project GAMBIN, Yann; ROSSY, Jeremie; SIERECKI, Prion-like behaviour in 3 years $611,995 Dementia Research the endosome in Grant Emma; ARIOTTI, Nicholas; VE, Thomas immunity: super-sized Fellow neurodegenerative disease signalling platforms? NHMRC COOPER, Matthew; BLASKOVICH, Mark Novel membrane-targeted 3 years $1,351,496 NHMRC Project GRATTEN, Jake & VISSCHER, Peter Genetic analysis of the 3 years $301,012 Development Grant A; PATERSON, David; ROBERTS, Jason A & antibiotics against drug- Grant relationship between HANSFORD, Karl A resistant Gram-positive parental age and risk of bacterial infections psychiatric disorders NHMRC ALEXANDROV, Kirill Point-of-Care test for 3 years $587,360 NHMRC Project MARTIN, Jennifer; COLLINS, Brett; & HU, Unraveling the dynamic 2 years $653,472 Development Grant immunosuppressant drugs Grant Shu-Hong Munc18a:Syntaxin1 NHMRC Equipment SMITH, Maree T; KUO, Andy; KHAN, Nemat Novel Pain therapeutics 1 year $213,462 interaction required for Grant U; KING, Glenn F; LEWIS, Richard J & discovery: Probing neurotransmission WILLIAMS, Craig M molecular mechanisms NHMRC Project ROGERS, Peter; MONTGOMERY, Grant & Identification and function of 4 years $1,180,912 NHMRC Project COOPER, Matthew & SCHEMBRI, Mark A Membrane-active antibiotics 4 years $942,299 Grant GIRLING J genes that increase risk for Grant against multi-drug resistant endometriosis Gram negative bacteria NHMRC Project YANG, Jian & MCRAE, Allan F Methods and software tool 4 years $573,999 NHMRC Project VETTER, Irina; MOBLI, Mohammadmehdi & A pharmacological approach 3 years $501,467 Grant for complex trait analyses Grant ZIMMERMANN, K. to define the contribution of using multi-omics data Nav1.7 to pain pathways NHMRC Project BOWLES, Josephine Exposing the mechanisms 3 years $536,562 NHMRC Project SCHRODER, Kate; BEZBRADICA Autophagic suppression of 3 years $556,950 Grant underlying mammalian Grant MIRKOVIC, Jelena & DERETIC, V. ASC inflammasomes meiotic onset NHMRC Project LITTLE, Melissa; SIMONS, Cas; SMYTH, Ian; Applying functional 4 years $1,229,316 NHMRC Research SWEET, Matt Pattern Recognition 5 years $622,655 Grant MALLETT, Andrew J & ALEXANDER, S. genomics to kidney disease Fellowship Receptors in Inflammation and Infection NHMRC Project SWEET, Matt & STOW, Jennifer L A new master adaptor 4 years $869,288 Grant protein for Toll-like Receptor Prostate Cancer ALEXANDROV, Kirill; STEIN, Viktor Development of highly 1 year $100,000 signalling Foundation of sensitive diagnostic test Australia for active form of prostate NHMRC Project HOGAN, Benjamin & SIMONS, Cas Characterisation of a newly 3 years $535,224 specific antigen Grant identified, indispensible, transcriptional regulator of The Kids’ Cancer WAINWRIGHT, Brandon J Targeting the cell cycle 2 years $260,420 lymphangiogenesis Project regulators CDK4/6 to treat medulloblastoma NHMRC Project FRANCOIS, Mathias; HARVEY, N. & Deciphering the 3 years $541,950 Grant SIERECKI, E. transcriptional program Shake It Up COOPER, Matthew; WOODRUFF, Trent; Blocking inflammasome- 2 years $293,979 that instructs lymphatic Australia Foundation SCHRODER, Kate; GORDON, Richard & induced neuroinflammation endothelial cell fate. ROBERTSON, Avril in PD with a potent, orally available small molecule NHMRC Project KOOPMAN, Peter A; BOWLES, Josephine & Molecular regulation 3 years $611,935 Grant SPILLER, Cassy of pluripotency in the The Michael J COOPER, Matthew; WOODRUFF, Trent; Blocking inflammasome- 2 years $881,931 mammalian germline Fox Foundation SCHRODER, Kate; GORDON, Richard & induced neuroinflammation Therapeutic Pipeline ROBERTSON, Avril in PD with a potent, orally NHMRC Project SMITH, Kelly & FRANCOIS, Mathias Examining an extracellular 4 years $732,600 Program available small molecule Grant matrix regulator required for cardiovascular development UQ Early Career KHALIL, Zeinab Wollamide B, a new anti- 1 year $24,500 Researcher Grant tubercular agent NHMRC Project COLLINS, Brett; ANGGONO, Victor & Sorting out the synapse: 3 years $631,966 Grant TEASDALE, Rohan D the role of intracellular UQ Early Career MA, Lin Lin Discovery and 1 year $24,760 trafficking in NMDA receptor Researcher Grant characterisation of novel homeostasis antagonists of the Kv10.1 channel with therapeutic NHMRC Project PARTON, Robert G; HALL, Tom; Molecular characterisation 4 years $951,321 potential Grant of transverse tubule development in skeletal UQ Early Career MUTTENTHALER, Markus Intranasal Oxytocin - does 1 year $24,962 muscle Researcher Grant it reach the central nervous system? NHMRC Project STOW, Jennifer L & BLUMENTHAL, Antje Cellular regulation of 4 years $859,288 Grant receptor signalling and UQ Fellowships COLL, Rebecca; Defining the mechanism 3 years $166,909 cytokine responses of action of MCC950, a small-molecule inhibitor of NHMRC Project CRAIK, David J & WANG, Conan K New drug leads for 3 years $619,986 NLRP3 for the treatment of Grant cholesterol inflammatory diseases

58 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 59 TOTAL GRANTING BODY INVESTIGATORS PROJECT TITLE DURATION GRANT RESEARCH UQ Fellowships STEPHENS, Evan D; Microalgae Biotechnology 3 years $197,818 FACILITIES for Commercial Applications UQ Foundation POWELL, Joseph Investigating genetic control 1 year $97,210 Research of disease susceptibility Excellence Awards through trans-eQTL With the Facility’s support, these and MASS SPECTROMETRY FACILITY – DVC(R) Funding regulation In partnership with industry, other studies published in 2016 have government and donors, IMB’s Mass Spectrometry Facility UQ Major CAPON, Robert; FAIRLIE, David; 4D Mass Spectrometer 1 year $240,000 uncovered important new knowledge in IMB have and continue to (MSF) provides researchers with state- Equipment and ALEWOOD, Paul F; COOPER, Matthew; health and disease. Infrastructure CRAIK, David J; KING, Glenn F; LEWIS, invest in major research of-the-art mass spectrometry, high- Richard J; HANKAMER, Benjamin; infrastructure – to provide IMB researchers will soon be able to performance liquid chromatography and see cancer cells grow, spread and robotic instrumentation. VETTER, Irina; WAINWRIGHT, Brandon J & leading technologies for FRANCOIS, Mathias respond to drugs in real time, with the The MSF provides technical advice scientists to facilitate cutting- establishment of the ACRF Cancer UQ Major KING, Glenn F; ALEWOOD, Paul F; CAPON, Patch-clamp 1 year $64,000 and research and training support edge research to address Ultrastructure and Function Facility. The Equipment and Robert; CLARK, Richard J; CRAIK, David electrophysiology platform in a number of mass spectrometric new Facility, which will be established in Infrastructure J; FRY, Bryan G; HANKAMER, Benjamin; for drug and insecticide global health, disease and applications, including investigating 2017 is the result of a $2.3 million grant LEWIS, Richard J; LYNCH, Joseph W; discovery sustainability issues. protein interactions and structures, amino from the Australian Cancer Research MOBLI, Mohammadmehdi; RASH, Lachlan; acid sequence determination, post- IMB’s research facilities span imaging, Foundation (ACRF) and $840 000 SCHROEDER, Christina; SIMONS, Cas & translational modification discovery and computational biology, bioinformatics, from the Australian Research Council others quantification, compound stability, and genome sequencing and analysis, Linkage Infrastructure, Equipment and bioavailability of potential therapeutics in UQ Major FRY, Bryan G; ALEWOOD, Paul F; Integrative blood 1 year $182,500 statistical genetics, genome editing, Facilities scheme. a range of biological systems. Equipment and ALEXANDROV, Kirill; ASGARI, Sassan; coagulation research core chemistry, structural biology and drug Infrastructure BARNES, Andrew C; CAPON, Robert; facility discovery, and high performance IMB SEQUENCING FACILITY In 2016, 138 unique users and 29 CHENEY, Karen L; CLARK, Richard J; computing. This means the Institute can research groups from UQ, CSIRO, COOPER, Matthew; CRAIK, David J; CRIBB, The IMB Sequencing Facility (ISF) take life science discoveries from the QIMR Berghofer Medical Research Thomas H; FANTINO, Emmanuelle; FAIRLIE, provides sequencing services to IMB, genome to drug design and application. Institute, University of the Sunshine David & others UQ and the research community Coast, Griffith University and James in the greater Brisbane region. The UQ Major THOMAS, Ranjeny; FRAZER, Ian H; GANDHI, Establishing a gnotobiotic 1 year $172,500 ACRF CANCER BIOLOGY Cook University accessed the Facility ISF provides library preparation and Equipment and Maher; EVANS, David; MORRISON, Mark; germ-free mouse facility IMAGING FACILITY for guidance and support with sequencing services on Illumina’s Infrastructure KHOSROTEHRANI, Kiarash; COOPER, experimental design, methodology, data The Australian Cancer Research NextSeq 500 and MiSeq platforms. Matthew; HUGENHOLTZ, Philip; acquisition, data processing, project Foundation (ACRF) Cancer Biology HOLTMANN, Gerald J; McGuckin, M.; PHIPPS, The Facility offers sample preparation reporting and publication. Imaging Facility is one of the largest and Simon; O CUIV, Paraic & BLUMENTHAL, Antje for sequencing of RNA from any most comprehensively equipped facilities The Facility supported a number of UQ Major TRAU, Matt; ROWAN, Alan E; MONTEIRO, Exosome and Bio/ 1 year $126,323 species, whole exome sequencing in Australia. Founded in 2010 with a $2.5 projects resulting in major discoveries Equipment and Michael J; ALEXANDROV, Kirill; YOUNG, Nanoparticle for human DNA and whole genome million ACRF grant, the facility houses and over 45 publications, including the Infrastructure Paul; MAHLER, Stephen M; WHITTAKER, Characterisation Facility sequencing for non-human species. 23 high-performance microscopes and use of mass spectrometry to study the Andrew K; THURECHT, Kristofer J; WANG, The ISF also offers sample preparation provides on-site expert technical support stability and bioavailability of potential Yuling; GRONDAHL, Lisbeth; TOTH, Istvan; and sequencing of custom projects and training. In 2016, over 200 unique therapeutics, protein biomarker BIRKETT, Greg R; BOTELLA, Jimmy & others including large-scale projects, for which users across UQ used the facility. discovery and quantification, toxin the Facility is equipped with a high- UQ Major MOYLE, Peter M; LITTLE, Peter J; CABOT, Establishing a High- 1 year $81,500 evolution, protein interaction networks By using techniques such as laser throughput sample preparation robot. Equipment and Peter J; PAREKH, Harendra; ROSS, Benjamin Throughput, Microwave- and peptide/protein composition of scanning and spinning disc confocal Infrastructure P; VETTER, Irina & TOTH, Istvan Assisted Automated Peptide In 2016, 26 unique research groups and animal venoms under varying biological microscopy, deconvolution, high- Synthesis Facility at PACE 39 individual users accessed the Facility conditions. throughput multi-well imaging and UQ Major POWELL, Joseph; COIN, Lachlan J M; Single Cell Transcriptomic 1 year $232,421 for sample preparation and sequencing 3D optical projection tomography, The Facility acknowledges funding Equipment and FRANCOIS, Mathias; HOGAN, Benjamin; Laboratory services. researchers made breakthroughs in a from the Australian Research Council Infrastructure PALPANT, Nathan; SIMONS, Cas; SMITH, range of areas. A notable breakthrough Linkage Infrastructure, Equipment and Kelly; BARTLETT, Perry; OSBORNE, came when researchers identified Facilities (LIEF) Project. Geoffrey; WRAY, Naomi; PORRELLO, Enzo; a mechanism involved in kidney WOLVETANG, Ernst & CARROLL, Bernard J development. Using this knowledge, they UQ Major Research BRERETON, Ian M; REUTENS, David C; Advanced Ultra-high Field 1 year $652,000 generated kidney organoids that contain Facility Fund MOBLI, Mohammadmehdi; SCHIRRA, Horst J; 900 MHz Biomolecular NMR multiple cell types arranged to mimic PIERENS, Gregory; KING, Glenn F; CRAIK, Facility human kidney structure and function. David J; LEWIS, Richard J; ALEWOOD, Paul F; FAIRLIE, David; COLLINS, Brett M; CAPON, Robert; GARSON, Mary J & others

60 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 61 ABOVE KARL BYRIEL, UQ ROCX CRYSTALLISATION AND X-RAY DIFFRACTION FACILITY ABOVE MELANIE OEY, SOLAR BIOFUELS RESEARCH HUB ABOVE ANNE KUNERT, QFAB

BIOMOLECULAR NMR FACILITY UQ ROCX CRYSTALLISATION AND QUEENSLAND FACILITY FOR SOLAR BIOTECHNOLOGY QFAB BIOINFORMATICS X-RAY DIFFRACTION FACILITY ADVANCED GENOME EDITING FACILITY IMB’s Biomolecular Nuclear Magnetic QFAB Bioinformatics (QFAB) provides customised Resonance (NMR) Facility makes the The UQ Remote Operation The Queensland Facility for Advanced IMB’s former Solar Biofuels Research services in bioinformatics, biostatistics and biodata powerful technique of NMR spectrometry Crystallisation and X-ray Diffraction Genome Editing (QFAGE) provides Centre was established as a research accessible to our research and industry (UQ ROCX) Facility provides research expert genetic modification (GM) hub for industry and university partners to life sciences and health researchers. clients. The Facility comprises a 600 training and support for protein services using CRISPR/Cas9 genome skilled in biotechnology, engineering Working closely with researchers, QFAB team members apply data MHz spectrometer equipped with a structure determination. editing and standard transgenic (TG) and systems development. The management, integration, analysis and visualisation techniques to unlock cryoprobe and autosampler, and a 500 mouse production technologies. research and production facility now the full value of large- scale biological and clinical datasets. This support includes protein MHz spectrometer equipped with a constitutes part of IMB’s new Centre for crystallisation condition screening, Established in January 2016, QFAGE robotic sample changer. Solar Biotechnology (CSB) and has a QFAB develop software and web applications, as well as maintaining, hosting crystal diffraction screening, data offers a flexible service to help life much broader scope of applications. and supporting tools developed by researchers. IMB research projects that Access is also available to the extensive collection, data processing, and sciences and biomedical research have been supported by QFAB include the development of a laboratory NMR infrastructure housed throughout structure determination. groups make the most of this valuable Located at Pinjarra Hills in Brisbane, management system to track the screening activities of the Community for IMB, most notably a 900 MHz technology that allows the modification the advanced pilot-scale test facility Open Antimicrobial Drug Discovery (CO-ADD) and deploying a computational The diffraction Facility has Queensland’s spectrometer equipped with a cryoprobe of DNA at the cell or whole organism develops high-efficiency microalgae platform to undertake large-scale multi-omics based research. brightest research X-ray source and and sample changer. The latter is an level. One of the major applications of systems and processes for the the state’s only robotic sample storage instrument of the Queensland NMR this approach is for the production of production of high value products as To empower researchers in mastering their data generation and analysis, and retrieval system, which allows Network and is the most powerful state- animal or cell models of human disease. well as bulk commodities. These include QFAB has developed a training portfolio and offer workshops and courses for multiple data sets to be collected of-the-art NMR spectrometer in Australia. foods, renewable fuels, advanced covering statistics, data processing and bioinformatics. Consultations without user intervention. The Facility is available on a user-pays bioproducts and bioremediation. during weekly clinics are also available to researchers who require Key discoveries made in 2016 system to researchers within IMB and assistance with research projects and grant applications. In 2016, 66 unique users accessed using the facility included structural across UQ, making mice with a number Facility capabilities within the CSB include the Facility for its high-throughput characterisation of plant defensins of types of genomic modifications. strain purification, cryopreservation, QFAB’s systems biology platform consists of leading software packages, applications, namely crystallisation having antifungal potential, and CRISPR/Cas9 approaches offered nutrient and light optimisation, data repositories and workflow engines deployed in a scalable high- condition screening, especially for of numerous venoms (from cone include gene knockout, insertions, metabolic engineering, high-value performance computational environment. This platform enables membrane proteins; and screening snails, snake and scorpion); and the modeling small specific DNA changes, product development and screening, investigations across the biological continuum by combining bioinformatics fragment libraries for drug leads. experimental structure confirmation of and the generation of conditional alleles photobioreactor and raceway system and cheminformatics approaches. computationally designed hyperstable Collectively, users performed 176,064 to allow gene disruption in a spatio- design, and technoeconomic analysis. QFAB Bioinformatics partners with UQ, Queensland University of constrained peptides. crystallisation experiments, over temporal manner. Following the establishment of the new Technology and Griffith University. 800 data sets were collected at The Facility is available on a user-pays The mouse operations of QFAGE are Centre at the end of 2016, the pilot-scale the Australian Synchrotron by UQ system to researchers from a range of directed by Professor Peter Koopman test facility at Pinjarra Hills is currently ROCX Users from over 2600 frozen scientific disciplines both within IMB with the support of Facility Manager Dr being upgraded. The new Centre for crystals shipped.Users also collected and across UQ. The Facility also holds Johnny Huang. Late in 2016 the facility Solar Biotechnology Pilot Plant will 16 in-house diffraction data sets collaborations with researchers from was expanded to include genome include additional capabilities and and published 14 scientific papers other Australian universities as well as editing in human cell lines, resulting in facilities such as improved containment supported by UQ ROCX access in 2016. several international collaborations, the appointment of Dr Nathan Palpant and safety, enhanced monitoring and most recently with scientists from as co-director of QFAGE. control systems, extensive equipment Belgium, China, and the United States. upgrades, new sterilisation facilities, and PC2 laboratories.

62 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 63 18. Gratten, J. (2016) Rare variants 26. Koay, H., Gherardin, N., Enders, 33. Patel, J., Seppanen, E., Rodero, are common in schizophrenia. Nature A., Loh, L., Mackay, L., Almeida, C. M., Wong, H., Donovan, P., Neufeld, Neuroscience, 19(11): 1426-1428 doi: et al. (2016) A three-stage intrathymic Z. et al. (2016) Functional definition of PUBLICATIONS 10.1038/nn.4422 IF: 29.298 development pathway for the mucosal- progenitors versus mature endothelial associated invariant T cell lineage. cells reveals key SoxF-dependent 19. Groß, C., Mishra, R., Schneider, K., Nature Immunology, 17(11): 1300-1311. differentiation process. Circulation. doi: Médard, G., Wettmarshausen, J., Dittlein, doi: 10.1038/ni.3565 IF: 20.004 10.1161/CIRCULATIONAHA.116.024754 D. et al. (2016) K+ efflux-independent IF: 14.43 NLRP3 inflammasome activation by 27. Lee, N., Fok, K., White, A., Wilson, small molecules targeting mitochondria. For a full list of 2016 publications please visit imb.uq.edu.au/publications N., O’Leary, C., Cox, H. et al. (2016) 34. Poznik, G., Xue, Y., Mendez, F., Immunity, 45(4): 761-773. doi: 10.1016/j. Neogenin recruitment of the WAVE Willems, T., Massaia, A., Sayres, M. et immuni.2016.08.010 IF: 24.082 regulatory complex maintains adherens al. (2016) Punctuated bursts in human junction stability and tension. Nature male demography inferred from 1,244 20. Guo, Z., Murphy, L., Stein, V., Communications, 7(11082). doi: 10.1038/ worldwide Y-chromosome sequences. Johnston, W., Alcala-Perez, S. & HIGH-IMPACT PEER REVIEWED PAPERS* ncomms11082 IF: 11.329 Nature Genetics, 48(6): 593-599. doi: Alexandrov, K. (2016) Engineered PQQ- 10.1038/ng.3559 IF: 31.616 glucose dehydrogenase as a universal 28. Li, J., Woods, S., Healey, S., 1. Arbore, G., West, E., Spolski, R., 7. Bussotti, G., Leonardi, T., Clark, M., 12. Eggers, S., Sadedin, S., van den biosensor platform. Journal of the Beesley, J., Chen, X., Lee, J. et al. 35. Secrier, M., Li, X., De Silva, N., Robertson, A., Klos, A., Rheinheimer, Mercer, T., Crawford, J., Malquori, L. Bergen, J., Robevska, G., Ohnesorg, T., American Chemical Society, 138(32): (2016) Point mutations in Exon 1B of Eldridge, M., Contino, G., Bornschein, C. et al. (2016) T helper 1 immunity et al. (2016) Improved definition of the Hewitt, J. et al. (2016) Disorders of sex 10108-10111. doi: 10.1021/jacs.6b06342 APC reveal gastric adenocarcinoma J. et al. (2016) Mutational signatures requires complement-driven NLRP3 mouse transcriptome via targeted RNA development: insights from targeted gene IF: 13.038 and proximal polyposis of the stomach in esophageal adenocarcinoma define inflammasome activity in CD4+ T cells. sequencing. Genome Research, 26(5): sequencing of a large international patient as a familial adenomatous polyposis etiologically distinct subgroups with 21. Herberg, J., Kaforou, M., Wright, Science, 352 (6292): 1424+-U95. doi: 705-716. doi : 10.1101/gr.199760.115 cohort. Genome Biology, 17(1). doi: variant. American Journal of Human therapeutic relevance. Nature Genetics, V., Shailes, H., Eleftherohorinou, H., 10.1126/science.aad1210 IF:34.661 10.1186/s13059-016-1105-y Genetics, 98(5): 830-842.doi: 10.1016/j. 48(10): 1131-1141. doi: 10.1038/ng.3659 IF: 11.351 IF: 11.313 Hoggart, C. et al. (2016) Diagnostic test ajhg.2016.03.001 IF: 10.794 IF: 31.616 2. Baile, P., Chang, D., Nones, K., Johns, 8. Cao, M., Allison, L.Dix, T. & Boden, 13. Eskandari, S., Guerin, T.Toth, I. accuracy of a 2-transcript host RNA A., Patch, A., Gingras, M. et al. (2016) M. (2016) Robust estimation of & Stephenson, R. (2016) Recent signature for discriminating bacterial 29. Masters, S., Lagou, V., Jéru, I., 36. Wan, J. & Alewood, P. (2016) Genomic analyses identify molecular evolutionary distances with information advances in self-assembled peptides: vs viral infection in febrile children. Baker, P., Van Eyck, L., Parry, D. et al. Peptide-decorated dendrimers and their subtypes of pancreatic cancer. Nature, theory. Molecular Biology and Evolution, Implications for targeted drug delivery The Journal of the American Medical (2016) Familial auto inflammation with bioapplications. Angewandte Chemie - 531(7592): 47-52. doi: 10.1038/ 33(5): 1349-1357. doi: 10.1093/molbev/ and vaccine engineering. Advanced Association, 316(8): 835-845. doi: neutrophilic dermatosis reveals a novel International Edition, 55(17): 5124-5134. nature16965 IF: 38.138 msw019 IF: 13.649 Drug Delivery Reviews. doi: 10.1016/j. 10.1001/jama.2016.11236 IF: 37.684 regulatory mechanism of pyrin activation. doi:10.1002/anie.201508428 IF: 11.709 addr.2016.06.013 IF: 15.606 Science Translational Medicine, 8(332): 3. Basiorka, A., McGraw, K., Eksioglu, 9. Carstens, B., Berecki, G., Daniel, J., 22. Hoang, H., Driver, R., Beyer, R., Hill, 37. Wang, C., King, G., Conibear, A., 1-9. doi: 10.1126/scitranslmed.aaf1471 E., Chen, X., Johnson, J., Zhang, L. et Lee, H., Jackson, K., Tae, H. et al. (2016) 14. Field, Y., Boyle, E., Telis, N., Gao, T., de Araujo, A., Plisson, F. et al. (2016) Ramos, M., Chaousis, S., Henriques, IF: 15.843 al. (2016) The NLRP3 inflammasome Structure-Activity Studies of Cysteine- Z., Gaulton, K., Golan, D. et al. (2016) Helix nucleation by the smallest known S. et al. (2016) Mirror images of functions as a driver of the Rich α-Conotoxins that Inhibit High Detection of human adaptation during α-helix in water. Angewandte Chemie 30. McWilliam, H., Eckle, S., Theodossis, antimicrobial peptides provide reflections myelodysplastic syndrome phenotype. Voltage-Activated Calcium Channels the past 2000 years. Science: 1-10. doi: (International Edition), 55(29): 8275-8279. A., Liu, L., Chen, Z., Wubben, J. et al. on their functions and amyloidogenic Blood, 128(25): 2960-2975. doi: 10.1182/ via GABAB Receptor Activation 10.1126/science.aag0776 IF:34.661 Doi:10.1002/anie.201602079 IF: 11.709 (2016) The intracellular pathway for the properties. Journal of American blood-2016-07-730556 IF:11.841 Reveal a Minimal Functional Motif. presentation of vitamin B–related antigens Chemical Society, 138(17): 5706-5713. 15. Fu, T., Li, Y., Lu, A., Li, Z., Vajjhala, 23. Humphris, J., Patch, A., Nones, Angewandte Chemie - International by the antigen-presenting molecule MR1. doi: 10.1021/jacs.6b02575 IF: 13.038 4. Bhardwaj, G., Mulligan, V., Bahl, C., P., Cruz, A. et al. (2016) Cryo-EM K., Bailey, P., Johns, A., McKay, S. Edition, 55(15): 4692-4696. doi: 10.1002/ Nature Immunology, 17(5): 531-537. doi: Gilmore, J., Harvey, P., Cheneval, O. structure of caspase-8 tandem et al. (Available online 15/11/2016) 38. Wee, K. & Yap, A. (2016) anie.201600297 IF: 11.709 10.1038/ni.3416 IF: 2.004 et al. (2016) Accurate de novo design DED filament reveals assembly and Hypermutation in pancreatic cancer. Biomechanical guidance helps elongate of hyperstable constrained peptides. 10. Castro, J., Harrington, A., Garcia- regulation mechanisms of the death- Gastroenterology, 152(1): 68-74.e2. 31. Murray, D., Jahnel, M., Lauer, J., a lumen. Nature Cell Biology, 18(3): 255- Nature, 538(7625): 329-335. doi: Caraballo, S., Maddern, J., Grundy, L., inducing signaling complex. Molecular doi:10.1053/j.gastro.2016.09.060 doi: Avellaneda, M., Brouilly, N., Cezanne, 257. doi: 10.1038/ncb3319 IF: 18.699 10.1038/nature19791 IF: 38.138 Zhang, J. et al. (2016) αConotoxin Vc1.1 Cell, 64(2): 236-250. doi: 10.1016/j. 10.1053/j.gastro.2016.09.060 IF: 16.716 A. et al. (2016) An endosomal tether 39. Zhou, F., Cao, H., Zuo, X., Zhang, inhibits human dorsal root ganglion molcel.2016.09.009 IF:13.958 undergoes an entropic collapse to bring 5. Bowles, J., Feng, C., Miles, K., 24. Karunarathne, D., Horne-Debets, T., Zhang, X., Liu, X. et al. (2016) Deep neuroexcitability and mouse colonic vesicles together. Nature, 537(7618): 107- Ineson, J., Spiller, C. & Koopman, P. 16. Gaidt, M., Ebert, T., Chauhan, D., J., Huang, J., Faleiro, R., Leow, C., sequencing of the MHC region in the nociception via GABAB receptors. Gut. 111. doi: 10.1038/nature19326 IF: 38.138 (2016) ALDH1A1 provides a source of Schmidt, T., Schmid-Burgk, J., Rapino, F. Amante, F. et al. (2016) Programmed Chinese population contributes to doi: 10.1136/gutjnl-2015-310971 IF: meiosis-inducing retinoic acid in mouse et al. (2016) Human monocytes engage death-1 ligand 2-mediated regulation 32. Osteen, J., Herzig, V., Gilchrist, J., studies of complex disease. Nature 14.921 fetal ovaries. Nature Communications, an alternative inflammasome pathway. of the PD-L1 to PD-1 axis is essential Emrick, J., Zhang, C., Wang, X. et al. Genetics, 48(7): 740-746. doi: 10.1038/ 7: 10845.1-10845.8. doi: 10.1038/ 11. Clairfeuille, T., Mas, C., Chan, A., Immunity, 44(4): 833-846. doi: 10.1016/j. for establishing CD4+ T cell immunity. (2016) Selective spider toxins reveal a ng.3576 IF: 31.616 ncomms10845 IF: 11.329 Yang, Z., Tello-Lafoz, M., Chandra, immuni.2016.01.012 IF: 24.082 Immunity, 45(2): 333-345. doi: 10.1016/j. role for the Nav1.1 channel in mechanical 40. Zhu, Z., Zhang, F., Hu, H., Bakshi, M. et al. (2016) A molecular code for immuni.2016.07.017 IF: 24.082 pain. Nature, 543(7608): 494-499. doi: 6. Budden, K., Gellatly, S., Wood, D., 17. Gherardin, N., Keller, A., Woolley, R., A., Robinson, M., Powell, J. et al. (2016) endosomal recycling of phosphorylated 10.1038/nature17976 IF: 38.138 Cooper, M., Morrison, M., Hugenholtz, Le Nours, J., Ritchie, D., Neeson, P. et 25. Kassam, I., Lloyd-Jones, L., Integration of summary data from GWAS cargos by the SNX27–retromer complex. P. et al. (2016) Emerging pathogenic al. (2016) Diversity of T cells restricted by Holloway, A., Small, K., Zeng, B., Bakshi, and eQTL studies predicts complex trait Nature Structural and Molecular links between microbiota and the the MHC class I-related molecule MR1 A. et al. (2016) Autosomal genetic control gene targets. Nature Genetics, 48(5): Biology, 23(10): 921-932. doi: 10.1038/ gut-lung axis.. Nature Reviews facilitates differential antigen recognition. of human gene expression does not 481-487. doi:10.1038/ng.3538 IF: 31.616 nsmb.3290 IF: 13.338 Microbiology, 15(1): 55-63. doi: 10.1038/ Immunity, 44(1): 32-45. doi: 10.1016/j. differ across the sexes. Genome Biology, nrmicro.2016.142 IF: 24.727 immuni.2015.12.005 IF: 24.082 17(1): 248.1-248.10. doi : 10.1186 /s13059- 016-1111-0 IF:11.313 * Impact factor >10

64 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 65 DISCOVERIES THANK YOU TO OUR INSPIRED BY LIFE MAJOR SUPPORTERS These life changing research projects are on the cusp of making an enormous difference in the world. Can you help?

Estate of Una Rosalind Drummond

Dr Rosamond Siemon HEALING HEARTS The Simon Axelsen Memorial Fund HELP US, HELP OUR DAUGHTERS: Heart disease is the single leading SOLVING ENDOMETRIOSIS cause of death in Australia. One Australian dies of Coronary Heart Disease Inside one in ten women an invasive disease is ravaging every 27 minutes. Its no wonder the heart is reproductive and surrounding organs. It causes serious at the centre of a multitude of IMB's research pain and infertility. It’s called endometriosis and it’s strongly projects with the UQ Centre for Cardiac and influenced by genetics. Vascular Biology. They are discovering more Using advanced techniques for gene mapping, Professor about the genes, cells and tissues involved Grant Montgomery and his research team are leading a in vascular formation, cardiac development global effort to identify the genes that increase a woman’s and cardiovascular regeneration every day. risk for endometriosis. Funding will open the door to effective How does a heart grow? Understanding the prevention, diagnosis and targeted treatment. fundamentals of development is the first step to creating new treatments. Your support will help us save the lives of patients suffering genetic and acquired heart disease.

ONGOING, DEBILITATING PAIN – AND THE VENOM PROGRESSING A NEW PEPTIDE THAT COULD TREATMENT FOR STROKE SWITCH IT OFF TO HUMAN CLINICAL TRIALS One in five Australians lives with ongoing pain. Stroke is the second leading cause of death worldwide. In Changes to their sensory neurons (the network of Australia, there will be one stroke every 10 minutes in 2017. nerve cells that transmits pain messages to the brain) Every year, five million survivors are left with a permanent force their nerves to keep firing unnecessarily. disability. There are no drugs available to protect the brain Dr Irina Vetter and her team may have found a way from stroke-induced damage. to switch it off. They’ve found a venom-derived But Professor Glenn King’s research team has identified compound that targets a protein on a nerve whose a potential new treatment that’s showing great promise role is to signal pain. The compound has exciting in pre-clinical trials. It massively reduces the brain prospects as a pain drug. damage following stroke and improves outcomes when The group is confident that the drug will be effective administered up to eight hours after stroke has occurred. against common types of acute pain and are Your support will accelerate this world first, novel hopeful that it will be useful in treating a wide variety treatment through to human clinical trials. of disease-related pain. Your support will enable discovery and translation of innovative, effective The Institute for Molecular Bioscience acknowledge with thanks our supporters treatments for pain. who have donated to various research programs throughout 2016.

Maureen O’Shea, IMB Director of Advancement +61 7 3346 2185 [email protected]

66 IMB YEAR IN REVIEW IMB YEAR IN REVIEW 67 Building 80, 306 Carmody Road The University of Queensland St Lucia Qld 4072

twitter.com/IMBatUQ facebook.com/ InstituteforMolecularBioscience youtube.com/imbatuq

imb.uq.edu.au

Executive Office Marketing and Communications Postgraduate Office +61 7 3346 2112 +61 7 3346 2155 +61 7 3346 2100 [email protected] [email protected] [email protected]

Advancement Partnership and Engagement +61 7 3346 2185 +61 7 3346 2194 [email protected] [email protected]

CRICOS provider number: 00025B